Pharmacy Enterprise Customization System (PECS) User Guide



Version 3.0

July 2014

Department of Veterans Affairs Office of Information and Technology (OIT) Product Development

Revision History

Each time this manual is updated, the Title Page lists the new revised date and this page describes the changes. No Change Pages document is created for this manual. Replace any previous copy with this updated version.

Date	Revised Pages	Patch Number	Description of Change
07/18/2014	All	PREC*3.0*1	Changed date to real release date (month) Marella Colyvas
05/30/2014	All	PREC*3.0*1	Reviewed and fixed typos from search and replace Marella Colyvas
05/27/2014	i-vi; all	PREC*3.0*1	Changed format of Revision History pages; changed FDB-DIF to FDB MedKnowledge Framework Marella Colyvas
05/08/2014	All	PREC*3.0*1	Made additional changes per CPS Marella Colyvas
05/07/2014	All	PREC*3.0*1	Made changes per CPS: graphics caption formatting, added links, created new heading for cross-reference purposes (Drug Pair Customization; changed "Records You Can Modify" to Modifying Records.") Marella Colyvas
03/13/2014	All	PREC*3.0*1	Added changes from CPS Marella Colyvas
02/13/2014	All	PREC*3.0*1	Added Alt Text for Section 508 Compliance Marella Colyvas
02/12/2013	55-58	PREC*3.0*1	Added FDB Drug Pair Content Marella Colyvas
02/11/2013	All	PREC*3.0*1	Updated for PECS 3.0 B Holihan
02/08/2013	All	PREC*3.0*1	Some formatting changes & edits; changed two screen shots in prep for PECS 3.0 Marella Colyvas

Date	Revised Pages	Patch Number	Description of Change
02/07/2013	53, vii	PREC*2.2*1	Updated graphic on Page 53 to ensure caption remained with image; Updated TOC B Holihan
02/07/2013	All	PREC*2.2*1	Updated Title Page to reflect Release month Updated Revision History order Updated Footer to include version number, release date. B Holihan
06/26/2012	Title Page	PREC*2.2*1	Updated title page to reflect the update month Marella Colyvas
06/13/2012	All	PREC*2.2*1	Updated to address Sonia T, Joanne C comments. B Holihan
06/12/2012	All	PREC*2.2*1	Updated to address Radu C comments of 06/11/12 B Holihan
05/31/2012	101-108	PREC*2.2*1	Entered nearly all of Joanne's comments re: FDB Comparison Reports. Marella Colyvas
05/23/2012	All	PREC*2.2*1	Updated TOC; changed some heading levels; replaced screen shots for Requestor & Approver home pages; adjusted pagination and section breaks Marella Colyvas
05/09/2012	61-62	PREC*2.2*1	Updated Quick Drug Pair selection. B Holihan
05/08/2012	84-85	PREC*2.2*1	Added screen capture to Null Drug Pair section; Reduced size of Custom Update samples Marella Colyvas
5/07/2012	84	PREC*2.2*1	Added sentence at the end of the Null Drug Pair write-up to contain info about the date from the FDB update. Marella Colyvas

Date	Revised Pages	Patch Number	Description of Change
05/04/2012	84-85	PREC*2.2*1	Added more information to Release Manager. Still needs better explanations of screen captures; added Null Drug Pairs write-up to Administrator Role (Julie's); added write-up on Quick Drug Pair Selection; added information about CCR5122 in User Guide in the Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction section. Marella Colyvas
5/04/2012	39	PREC*2.2*1	Clarified the "Also note: If you wish to put a Drug-Drug Interaction (DDI)" statement at the end of the Notification of Drug Pairs Needing Action for the Approved Drug-Drug Interaction section. Joanne Callahan
05/03/2012	2, 62	PREC*2.2*1	Added explanation of Custom Update File in Release Manager section; updated definition of Administrator on pages 2 and 62 (added fact they can initiate null drug pair removal). Updated write-up on Quick Drug Pair Selection Marella Colyvas
4/27/2012	61-62; 75	PREC*2.2*1	Added PBM feedback to Release Manager write-up; added short write-up on Quick Drug Pair Selection Marella Colyvas
4/12/2012	39; 75	PREC*2.2*1	More changes to Drug Pair Notification; added Release Manager write-up Marella Colyvas
4/11/2012	39	PREC*2.2*1	More changes to Drug Pair Notification Marella Colyvas

Date	Revised Pages	Patch Number	Description of Change
4/9/2012	39	PREC*2.2*1	Renamed the Title of the Drug Pair Notification Section (was "Working with Drug Pairs") Marella Colyvas
4/6/2012	50-51; 75-76	PREC*2.2*1	Edited and obtained new screen shots for Multiple DDI records to one FDB; attempted to write up Release Manager but need more information. Marella Colyvas
3/23/2012	39	PREC*2.2*1	Drafted Drug Pair Notification Marella Colyvas
3/15/2012	50-53	PREC*2.2*1	Cleaned up Record Locking; made edits from Sonia on Creating Multiple Custom DDIs to One FDB Record and Prevention of Duplicate DP on Single Record Marella Colyvas
3/13/2012	51	PREC*2.2*1	Added information on Creating Multiple Custom DDIs to One FDB Record and Prevention of Duplicate DP on Single Record Marella Colyvas
03/12/2012	63; All	PREC*2.2*1	Added data on Forward/Reverse Monographs and Multiple DDIs to one FDB; included Lynn Teague's changes Marella Colyvas
02/17/2012	44	PREC*2.2*1	Completed Record Locking Marella Colyvas
02/16/2012	44	PREC*2.2*1	Made a few additions to Record Locking Marella Colyvas
02/10/2012	All	PREC*2.2*1	Made a few changes to the text on Edit panels Marella Colyvas

Date	Revised Pages	Patch Number	Description of Change
1/26/2012	All	PREC*2.2*1	Created text for Not Editing Single Drug Pair window; added some screen shots; still have to add Sonia's changes. Marella Colyvas
1/23/2012	All	PREC*2.2*1	Beginning of changes for PECS 2.2. Added new Read-Only screens for each concept; eliminated edit mode screen shots for now; Marella Colyvas
11/05/11	All	PREC*2.2*1	Edited information from customer on Action Statuses, and added information on Saved Queries Marella Colyvas
10/13/11	All	PREC*2.2*1	Added information on potential Easy Search/PECS Record discrepancy; changed a screen shot Marella Colyvas, Wendy Cobb
10/7/11	All	PREC*2.2*1	Reviewed and provided feedback / comments Hussain Kedwaii
10/6/2011	All	PREC*2.2*1	Added changes for 2.1 Marella Colyvas, Kristen Kriwox, Wendy Cobb
04/12/2011	All	PREC*2.2*1	Added edits from CPS. Marella Colyvas
12/08/2010 CR 3520	All	N/A (First Release)	Began changes for PECS v2.0, sprint 1, Professional Monograph and Historical Records Marella Colyvas
11/18/2010 CR 3391	All	N/A (First Release)	Edited changes requested by customer analyst prior to second (final) review by EIE Marella Colyvas

Date	Revised Pages	Patch Number	Description of Change
10/12/2010 CR 3391	All	N/A (First Release)	Updated elements found in Enterprise Infrastructure Engineering (EIE) review for Operational Readiness Testing (ORT) Marella Colyvas
4/14/2010	All	N/A (First Release)	Baseline Russell Chachula and Marella Colyvas

Table of Contents

Pharmacy Enterprise Customization System (PECS)	
Purpose	
· PECS Advantage	1
Security Roles	1
Identity Management	2
Process Flow	3
Transaction Flow	5
Customization Information	7
Drug-Drug Interaction and Professional Monograph	7
Duplicate Therapy	8
Dose Range	8
PECS Button List	8
Application Screens	11
Login	11
Instructions	11
Authentication Explanation	11
Home Page	13
My Request History	14
My Assigned Requests for Review	14
My Assigned Requests for Approval	15
My Assigned Requests for Deletion	15
Unassigned Requests	15
All Requests	15
Drug Pair Lookup Page	17
Advanced Query/Customization Page	21
Accessing the Advanced Query/Customization Page	21
The Query Builder Panel	23
How to Build a Query	23
And/Or Usage Example	25

Query Specifics	25
Save a Query	26
Run a Saved Query	26
Delete a Saved Query	27
Rename a Saved Query	27
Sort Query Results	28
Export Query Results	29
Query Errors	29
Add Default DRC Query	30
History of Changes	32
Modifying Records	35
Dose Range	35
Professional Monograph	36
Duplicate Therapy	37
Drug-Drug Interaction	37
Single Drug Pair Page Modification Not Allowed	38
Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction	39
Drug Pair Customization	40
Record Locking Feature	44
Creating Multiple VA Custom Drug-Drug Interactions to One FDB Record	50
Create Multiple DDIs per One FDB Record	51
Prevention of Two Users Adding Identical Drug Pairs to the Same DDI	53
Drug Pair Detail Page	55
VA Customized Drug Pair Detail Page	58
Quick Selection of Drug Pairs from the Selection List	61
Forward and Reverse Professional Monograph	63
Easy Search Query Page	65
Interactions for a Single Drug	68
Potential Discrepancy Between Easy Search Results and PECS Records	70
Easy Search Dose Range	73
User Roles	75

Requestor	75
Approver	75
Release Manager	75
Update Files Explained	76
Administrator	79
Customize Settings	79
Approver User Settings	82
Null Drug Pair Removal Process	
Sample Modification Scenarios	
Duplicate Therapy Modification	87
Process Steps	87
Duplicate Therapy Approval	89
Process Steps	89
Drug Interaction Research	89
Process Steps for Severity Check, Case 1	89
Drug Interaction Severity Change	89
Process Steps for Editing Case 1	90
Drug Interaction Severity Change	93
Process Steps for Editing Case 2	93
Remove Drug Pair from Interaction	95
Process Steps	95
Create Professional Monograph	96
Process Steps	96
Reports	
Customization Reports	
FDB Custom Dose Range Report	
FDB Custom Drug-Drug Interaction Report	
FDB Custom Duplicate Therapy Report	
FDB Custom Professional Monograph Report	100
Deleted Monograph Customization Report	100
Null Drug Pairs Customization Report	100
FDB Comparison Reports	101
Structure of the FDB Comparison Report	101

Drug-Drug Interaction/Drug Pair Report	103
Duplicate Therapy Report	107
Dose Range Report	

List of Figures

Figure 1: PECS Customization Life Cycle	3
Figure 2: Action Statuses	5
Figure 3: Drug-Drug Interaction Relationship	7
Figure 4: KAAJEE Login Screen	. 11
Figure 5: Home Page for Approver (Partial View)	. 13
Figure 6: Home Page for Requestor	. 14
Figure 7: Drug-Drug Pair Query Window	. 17
Figure 8: Sample Query	. 18
Figure 9: Drug Pair Query Result	. 18
Figure 10: Default Position of "Request Assigned To"	. 19
Figure 11: Re-positioned "Request Assigned To" Column	. 19
Figure 12: Accessing the Advanced Query / Customization Page	. 21
Figure 13: Access Advanced Query/Customization from the Home Tab	. 21
Figure 14: Sorting Query Results	. 28
Figure 15: Query Error Message	. 29
Figure 16: Default Dose Range Query Window	. 30
Figure 17: Results from Building a Dose Range Query with Default DRC Query	. 31
Figure 18: History of Changes On-Screen Table	. 32
Figure 19: Changes Shown in FDB Comparison Report	. 33
Figure 20: Dose Range Record - Read-Only	. 35
Figure 21: Professional Monograph Record- Read Only	. 36
Figure 22: Duplicate Therapy Record - Read-Only	. 37
Figure 23: Drug-Drug Interaction Panel - Read Only	. 37
Figure 24: Home Page with Approved DDIs with Pending Drug Pairs	. 39
Figure 25: My Assigned DDIs with Pending Drug Pairs List	. 40
Figure 26: Drug-Drug Interaction Window	. 40
Figure 27: List of Drug Pairs You Can Act On	. 41
Figure 28: Assigned To Drop-Down When Adding a Drug Pair	. 42
Figure 29: Assigned To Drop Down When Editing Drug Pairs	. 43
Figure 30: DDI FDB with Custom Records	. 50
Figure 31: Drug Pair Detail Page (Read Only)	. 55
Figure 32: Example of FDB Drug Pair Customized for One DDI, Deleted from Another, and	
Customized for a Third	. 56
Figure 33: Example of Drug Pair Customized for One DDI, Rejected from the Same DDI, and	
Customized Again for Another DDI	. 57
Figure 34: VA Customized Drug Pair	. 58
Figure 35: Select Single Drug Pairs	. 61
Figure 36: Range of Drug Pairs Selected with Shift Key	. 61
Figure 37: Forward/Reverse DDIs with Professional Monographs, Custom Update File Created	Ł
by Release Manager	. 63
Figure 38: Initial Easy Search Window	. 65
Figure 39: Select Drug-Drug Interaction with Professional Monograph and Duplicate Therapy.	. 65
Figure 40: Severity Levels 1 and 2 Selected, and Drug Name to Search	. 66

Figure 41: Partial Easy Search Results - Drug-Drug Interaction	67
Figure 42: Partial Easy Search Results: Professional Monograph	67
Figure 43: Partial Easy Search Results - Duplicate Therapy	68
Figure 44: Easy Search DDI Record	71
Figure 45: Referenced PECS Record with Name Discrepancy	72
Figure 46: Custom Update Zip File	77
Figure 47: Custom Update Text File	77
Figure 48: Full Update File	
Figure 49: Custom Drug-Drug Interaction Full Update File	
Figure 50: Null Drug Pair Removal Process Complete	85
Figure 51: Sample FDB Comparison Report - Duplicate Therapy	101
Figure 52: FDB Incremental Update Section Items	102
Figure 53: Example of a "No Data Found" Message in an FDB Comparison Report	103
Figure 54: DDI-DP Report	103
Figure 55: First Half of FDB Comparison Report for DDI	105
Figure 56: Second Half of FDB Comparison Report for DDI	105
Figure 57: Contents of the FDB Interaction ID tab, i.e., Drug Pairs Updated by FDB:	106
Figure 58: Display of All Customizations Done for an FDB Record	106
Figure 59: FDB Comparison Report - Duplicate Therapy	107

Pharmacy Enterprise Customization System (PECS) Overview

Purpose

The Pharmacy Enterprise Customization System (PECS) is a Graphical User Interface (GUI) application that currently allows users to customize the contents of the following five business concepts:

- Drug-Drug Interaction
- Drug Pair
- Duplicate Therapy
- Dose Range
- Professional Monograph

The purpose of this user guide is to provide a general overview of the PECS application, as well as more detailed working information. It also provides reference material and task-based instructions for entering and approving Drug-Drug Interaction, Drug Pair, Duplicate Therapy, Dose Range, or Professional Monograph Customization Requests.

PECS Advantage

- All customizations will be performed at the national level to provide consistent order checks between facilities
- Use of First DataBank for drug interaction, duplicate therapy, and dosing data.
- More specificity in drug interaction order checks with the ability to include or exclude dose routes.
- More specificity in duplicate therapy order checks with FDB data.
- Weekly FDB updates with monthly customization updates.
- More frequent customization updates when needed.

Security Roles

The PECS application is accessible only by users signed directly into the VA network, or by users signed into the VA network via the RESCUE client. User authentication into the VA network is a precondition of PECS application access. Application authentication and authorization will be controlled by the VA Kernel Authentication and Authorization for J2EE (KAAJEE) security Application Programming Interface (API).

In order to log in to the application, each user must have a valid VistA account at a local or national facility, since KAAJEE delegates user authentication to VistA. At the application's login screen, users are prompted for their access and verify codes and will be allowed to select the VistA institution which issued their credentials*

Identity Management

Authorization is handled through the use of specific VistA security keys. PECS doesn't assign individual permissions to users. Instead, it defines a number of roles for its users (requestor, approver, release manager and administrator) and associates a set of permissions with each of them. These roles are mapped to security keys as follows.

PECS Role	VistA Security Key
Requestor	PSS_CUSTOM_TABLES_REQUESTOR
Approver	PSS_CUSTOM_TABLES_APPROVER
Release Manager	PSS_CUSTOM_TABLES_REL_MAN
Administrator	PSS_CUSTOM_TABLES_ADMIN

Depending on the permissions needed by a user, the appropriate role is determined and the corresponding key assigned to their account. The user provisioning process is part of the VistA system and is thus not documented here. Password changes, account activation/inactivation, etc., must be performed through VistA. Refer to the appropriate documentation for details on user account management

Following is a list of roles available within the application, and a description of what each role can do:

Requestor: Create a customization request, modify their own requests, and run, save, and export queries.

<u>Approver</u>: Create, review, approve, modify, delete or reject customization requests; run, save, and export queries, and run reports. An approver can review but cannot approve their own requests.

<u>Release Manager</u>: Can run queries and view detail records. A Release Manager can generate an incremental or full Custom Update file, or download an existing Custom Update.

<u>Administrator</u>: Can run queries and view detail records. In addition, Administrators can modify field settings for each concept type, add or delete users to/from the approver role, and initiate the process to remove drug pairs that contain a null routed generic drug.

Process Flow

Here is a process diagram depicting the process life cycle. It depicts the high-level business process from the point at which a new interaction is created to when a file is available to be loaded to production.



Figure 1: PECS Customization Life Cycle

Figure 1 shows the life cycle of a customization change from the Requestor entry to the point the record is ready to be sent to the production FDB MedKnowledge Framework custom table. The updates and changes are made and maintained in a Staging Table. Records are not extracted until the Release Manager submits approved changes. Records are then formatted and placed in a directory where they will be updated to production. The process that updates these records uses software named DATUP.

Transaction Flow

The diagram below depicts the Action Statuses of a record's transition from creation to approval.



Figure 2: Action Statuses

Action Statuses

This list displays the different Action Statuses a VA customized record may go through as it steps through the approval workflow within PECS. Note that only seven of the following eleven states are displayed in the user interface - in other words, some of this information is "behind-the-scenes." It is included here as information only.

<u>New</u> - A new customization request has been created. If a user has the appropriate authority, they may modify the request (Modified) to be completed at a later point. Then, if they have the proper authority, they may submit the request as reviewed (Reviewed).

<u>Modified</u> - A user can make changes to their own New requests. The record will remain Modified until a user with the proper authority (Approver role) reviews the request and submits the request as Reviewed.

<u>Modified After Approve</u> - (displays as Modified) A user with the proper authority has requested a change in the Approved customization that requires another approval process.

<u>Modified After Delete</u> - (*displays as Modified*) A user with the proper authority has requested the deleted record be considered again for Approval with or without modifications. This requires another approval process.

<u>**Reviewed</u>** - This is the first stage of approval. A user with the proper authority (Approver role) reviews the new or modified customization request and submits it as Reviewed. The approver may also reject or modify the request. Note that an approver can review their own requests but not approve them.</u>

<u>Reviewed After Approve</u> - (*displays as Reviewed*) Modifications were made to an approved record. A user with the proper authority (Approver role) reviews the request and submits it as Reviewed. The Approver may also reject the request, in which case the record returns to the Approved state, or they may modify it.

<u>Reviewed After Delete</u> (displays as Reviewed)- Modifications were made to a deleted record. A user with the proper authority (Approver role) reviews the request and submits it as Reviewed. The Approver may also reject the request, in which case the record returns to Deleted state, or they may modify it.

<u>**Rejected</u>** - The customization request is in a Rejected state. At this point the user may make changes, resubmit, or keep the transaction in the rejected state. All records that are rejected or not approved will remain in that state and will be available to the user for any future changes.</u>

<u>Approved</u> – This is the second stage of approval. A user with the proper authority (Approver role) who did *not* submit the request as Reviewed will review the record and may approve, reject, or modify the request.

<u>**Delete**</u> <u>**Reviewed**</u>- The record remains active but a user with the proper authority (Approver role) has requested deletion of an existing approved customization.

<u>**Deleted**</u> – A user in the Approver role who did *not* submit the request for Deletion may delete the customization. If an Approver confirms the deletion, the record will remain active for potential future modifications.

Customization Information

Here is information on the basic types of customization that can be done with PECS.

Drug-Drug Interaction and Professional Monograph

This diagram displays how a drug interaction is tied to drug pairs and professional monographs:

Drug-Drug Interaction Relationship



Drug interaction now between routed generics within an interaction description that is also associated with a monograph.

Figure 3: Drug-Drug Interaction Relationship

FDB Drug-Drug interaction severity levels:

1 = Contraindicated

- 2 =Severe
- 3 = Moderate
- 9 = Undetermined severity Alternate therapy

Within the VA system, an FDB or VA Custom drug-drug interaction of severity level 1 will return a Critical order check and severity level 2 will return a Significant order check. Severity levels 3 and 9 will not return an order check.

Types of drug-drug interaction customizations include:

- Change in severity level
- Add or remove drug pairs
- Create drug interactions not found in FDB

Note: Due to the millions of possible drug pair combinations, you must be very specific on which two products are involved when reporting problems with the system.

Duplicate Therapy

The Duplicate Therapy concept allows you to specify the maximum number (0, 1, or 2) of duplicate therapy matches that can occur within a therapeutic class without creating an order check. A '0' duplicate allowance means only 1 medication from that therapeutic class can be on the patient profile without getting an order check (zero duplication). If a second drug from that class is added the provider gets the order check. If the allowance is '1', two drugs can be on the patient profile at once, the 3rd drug added would get the check (one duplication), etc.

The only type of Duplicate Therapy customization allowed is to increase or lower the duplicate therapy allowance for a therapeutic category.

Dose Range

Here is information about the Dose Range function:

- Dosing is based on the GCN Sequence Number (GCNSEQNO), a random number specific to all drug products with the same generic ingredient(s), route of administration, drug strength(s) and dosage form.
- Dosing is age-specific for most products. FDB has dosing for neonatal, infant, adolescent, adult, and geriatric. All ages are by days, for example, 18 years x 365= 6570 days.
- FDB also has indication-specific dosing, and dosing type. Examples of dosing type are loading, maintenance, single, initial.
- A typical product may have 30 or more dosing records when all variables are taken into consideration.
- The initial implementation of dosing order checks within VistA looks at the maximum single dose and daily dose range order checks using a common indicator.

PECS Button List

Here is a list of the buttons in PECS and their meanings. This list is alphabetical, not by window or function, as the buttons can display on many different windows and it depends upon user authority whether a button is visible.

- Active -- Displayed on the Query Result page. Opens an existing in-process request.
- Add Default DRC Query Found on the Dose Range Advanced Query page. When selected, Concept Type Equal to 6 AND Age High in Days Greater than or Equal to 6570 is added to the query builder.
- And Adds query criteria to a query that is being created for execution. This creates an "AND" clause with any other existing criteria.
- Approve Moves the request from the Reviewed status into the Approved status.
- **Cancel** Returns the user to the Home index page without saving any changes to the database for the request.
- Clear Query Clears the Query Builder form of any previously entered data.
- Customize Displayed on some pages to create a VA customization from an FDB record.

- Edit Displays on the detail pages of all concepts where the record is in Read-only mode. This button allows users to edit a particular detail page if it is not already in use by another user.
- Delete Moves the request from the Delete Reviewed status into the Deleted status.
- **Drug Pairs** Retrieves a list of possible drug pairs from the FDB MedKnowledge Framework database that are eligible to be added to the VA Custom Drug Interaction, and lists any existing custom drug pairs that the Drug Interaction may have.
- **Export** Creates a file of the results of an executed query that can be downloaded and opened in the Microsoft Excel program.
- **Historical** Displayed on the query result page. Opens a historic record as read-only.
- **Modify** Moves a request from New, Modified, Rejected, Approved or Deleted into the Modified status. Writes any changes made to the request to the database, and leaves the status in the Modified status.
- **Open** Displayed on the query result page. Opens an FDB record.
- **Open Blank Form** Found under the FDB results when querying Both VA and FDB records in Drug-Drug Interaction, Professional Monograph or Dose Range. Navigates the user to a blank form.
- **Or** Adds query criteria to a query that is being created for execution. This will create an "OR" clause with any other existing criteria.
- **Print Page** Calls the browser's print page functionality.
- **Query** Allows the user to submit a query to the system. If there are records that match the query parameters, they will be displayed in the results table.
- **Reject** Moves the request from the New, Modified, or Reviewed status into the Rejected status. When records that are modified after approval or deletion are rejected, the record returns to the approved or deleted state.
- **Save Query** Allows the user to save the executed query with a user-friendly name, available to be executed in the future.
- Submit As Reviewed Moves the request from the New, Modified or Rejected status into the Reviewed status.
- **Submit For Delete** Moves the request from the Approved status into the Delete Reviewed status.

Application Screens

Login

Instructions

The purpose of this screen is to provide an authorized user access to the system. Each user needs to select their site, then enter their current VistA access and verify codes,. which are their assigned/designated "User IDs" and passwords.

Note that authorization is handled through the use of specific VistA security keys. PECS doesn't assign individual permissions to users. Instead, it defines a number of roles for its users (Requestor, Approver, Release Manager and Administrator) and associates a set of permissions with each of them. To see the list, refer to <u>Identity Management</u> on page <u>2</u>.

Authentication Explanation

Application authentication and authorization is controlled by KAAJEE. Refer to VistA documentation for details on the user account maintenance.

If the response from the authentication request is successful via the KAAJEE API, KAAJEE returns a user profile object, which is used by the application to determine the user's role and permissions. On successful login, the system transfers the user to the Home page of the application.

Here is the login window:

System Announcements:
U.S. Government Computer System
U. S. government systems are intended to be used by authorized government network users for viewing and retrieving information only, except as otherwise explicitly authorized for official business and limited personal use in accordance with policy. Information from these systems resides on and transmits through computer systems and networks funded by the government. All access or use constitutes understanding and acceptance that there is no reasonable expectation of privacy in the use of Government networks or systems.
The data and documents on this system include Federal records that contain sensitive information protected by various Federal statutes, including the Privacy Act, 5 U.S.C. Section 552a, and veterans' records confidentiality statutes such as 38 U.S.C. Sections 5701 and 7332. Access to the data and records is on a need-to-know basis only.
All access or use of this system constitutes user understanding and acceptance of these terms and constitutes unconditional consent to review and action including (but not limited to) monitoring, recording, copying, auditing, inspecting, investigating, restricting access, blocking, tracking, disclosing to authorized personnel, or any other authorized actions by all authorized government and law enforcement personnel.
Unauthorized user attempts or acts to (1) access, upload, change, or delete information on this system, (2) modify this system, (3) deny access to this system, (4) accrue resources for unauthorized use or (5) otherwise misuse this system are strictly prohibited. Such attempts or acts are subject to action that may result in criminal, civil, or administrative penalties.
Login: PECS
Health Ver Var Access Code:
⊙ Sort by Station Number * ○ Sort by Station Name *
Institution: SAN FRANCISCO VAMC (662)
Login
* Persistent Cookie Used (more information).
Figure 4: KAAJEE Login Screen

Home Page

The Home page is the first page that the user is directed to after logging into the application. This page provides information about when the last update to the First DataBank DIF database tables occurred and also when the last customization update file was created. The purpose of the Home page is to provide the user with summary counts of the number of active customization records that the user can access.

The Home page is organized into panels containing specific information. Only panels that are appropriate to the role of the current user are displayed. Users in the "Requestor" role are shown only the "My Request History" panel. Users in the "Approver" role are shown nearly all available panels. The counts are organized by the action (Review/Approve/Delete) the user can perform on the customization records for each concept type (Professional Monograph, Dose Range, Drug-Drug Interaction and Duplicate Therapy). Additionally, the Home page provides details on the status of any active customization records that the user may have entered into the system (My Request History). This allows the user to track their own requests as they move through the approval process.

Clicking on the link to the number of records under each panel (if more than '0') will redirect the user to the Advanced Query/Customization tab with the "Build a Query" panel displaying the fields, filters and values that were queried against, in order to obtain the results showing in the "VA Table Results" panel. The "VA Table Results" panel contains the active records that match the items for the count displayed on the Home page.

The bottom of the home page (and every page) contains navigation links providing access to various areas of the system. These links are identical to the navigation tabs at the top of every page.

The following window	<i>w</i> displays an examp	ple of what a user	with the "Appr	over" role may	see on the home
page:					

PECS	RMACY ENTE	RPRISE SYSTEM						Welcome, TWO_APPROVER
Home Advanced Query/Custor	mization Easy	Search	Drug Pair Looku	p Reports	Help			
Velcome TWO_APPROVER	2							E
ast update to First DataBank DIF da	tabase occurred o	n: 11-23-201	2 version: 3.3					
ast customization update file creatio	in occurred on: 01	-31-2013						
My Request History								
Concept	New	Modified	Reviewed	Approved	Rejected	Deleted	All	
Drug-Drug Interaction	45	2	1	1	3	2	<u>61</u>	
Professional Monograph	2	0	1	1	2	2	8	
Duplicate Therapy	3	2	5	1	0	2	13	
Dose Range	6	4	3	2	1	0	<u>16</u>	
My Assigned Requests for Revi	iew							
Concept	Awaiting Revie	W						
Drug-Drug Interaction	Z							
Professional Monograph	4							
Duplicate Therapy	3							
Dose Range	1							
Approved Drug Drug Interactions With Pending Drug Pairs	1							

Figure 5: Home Page for Approver (Partial View)

This window displays an example of what a user with the "Requestor" role may see on the home page:

nome Auvanceu query/cu	Istomization	Easy Search	Drug Pair Looku	p Help				
Velcome TWO REQUES	STOR							Pao
								<u></u>
st update to First DataBank DI	F database occurr	ed on: 11-23-201	2 version: 3.3					
st customization update file cre	eation occurred or	1: 01-31-2013						
ly Request History								
Concept	New	Modified	Reviewed	Approved	Rejected	Deleted	All	
		3	1	1	0	1	<u>9</u>	
Drug-Drug Interaction	<u>3</u>				0	0	5	
Drug-Drug Interaction Professional Monograph	<u>3</u> 2	3	0	0	0			
Drug-Drug Interaction Professional Monograph Duplicate Therapy	3 2 0	3	0	0	1	0	3	
Drug-Drug Interaction Professional Monograph Duplicate Therapy Dose Range	3 2 0 2	3 2 1	0 0 0 0	0 0 1	1 0	0	<u>3</u> 6	



My Request History

Active customization records created by the logged in user (Requestor and Approver roles only). The results will be broken down into numbers of active records, created by the logged in user by the following Action Statuses: New, Modified, Reviewed, Approved, Rejected, Deleted and All.

New	The count is the number of active records in the "New" status created by the logged in user.
Modified	The count is the number of active records in the ""Modified" status created by the logged in user.
Reviewed	The count is the number of active records in the "Reviewed" and "Delete Reviewed" status created by the logged in user.
Approved	The count is the number of active records in the "Approved" status created by the logged in user.
Rejected	The count is the number of active records in the "Rejected" status created by the logged in user.
Deleted	The count is the number of active records in the "Deleted" status created by the logged in user.
All	The count is the number of all active records in any status, created by the logged in user.

My Assigned Requests for Review

Active customization records assigned to the logged in user to be reviewed. The Awaiting review count is the number of records that are in the "New" or "Modified" status, that have been assigned to the logged in user. This section will only be displayed for users in the Approver role.

My Assigned Requests for Approval

Active customization records assigned to the logged in user to be approved. These records have been "reviewed" by another "Approver" in the system. This section will only be displayed for users in the Approver role.

My Assigned Requests for Deletion

Active customization records assigned to the logged in user to be deleted. The records have been "delete reviewed" by another "Approver" in the system. This section will only be displayed for users in the Approver role.

Unassigned Requests

Active customization records in the approval process that have not yet been assigned to any user. These records may be in the Action Status of New, Modified, or Reviewed. This section will only be displayed for users in the Approver role.

All Requests

All active customization records currently in the system by status. The result detail will display the active records associated with the selected custom table summary. The categories are:

New	The count is the number of active records in the "New" status.
Modified	The count is the number of active records in the "Modified" status.
Reviewed	The count is the number of active records in the "Reviewed" and "Delete Reviewed" status.
Approved	The count is the number of active records in the "Approved" status.
Rejected	The count is the number of active records in the "Rejected" status.
Deleted	The count is the number of active records in the "Deleted" status.
All	The count is the number of all active records, by status. This is NOT a link, just informational

Drug Pair Lookup Page

If you have the proper authority, you can access the Drug Pair page by clicking the Drug Pair Lookup tab. It allows you to perform a quick query search on the most common elements.

On this page, you can perform a simplified query where a record search is performed from the FDB MedKnowledge Framework and VA Custom tables. Simply enter filter data in any or all of the four entry fields (Drug A, Drug B, Interaction, or Severity Level Code). The resulting data is displayed under the VA Table Results and FDB Table Results panels. These consist of active customized Drug Pair records from the VA custom database (DB), which are available for modification, as well as their related Drug Pair records from the FDB DB from which they were customized.

Field names are as follows:

- Drug A The name (or partial name) of one generic drug associated with an interaction.
- Drug B The name (or partial name) of a second generic drug associated with an interaction.
- Interaction An assigned drug interaction ID number or Description associated with the drug pair of Drug A and Drug B.
- Severity Level Code Drop down list of available severity codes.

UNITED STATES DEPARTMENT OF VETER	ANS AFFAIRS	× ×				
PECS	RMACY EN	TERPRISE N SYSTEM				Welcome, FOUR_APPROVER Logout
Home Advanced Query/Custo	mization Ea	asy Search Drug Pair Lookup R	Reports Help			
Drug Pair Lookup						<u>Page Help</u>
The Drug Pair Lookup page allows u Interaction and/or select a value for S anywhere in the specified field will be To begin your search for drug pairs, o	isers to search f Severity Level Co e returned. complete any of	for VA custom drug pairs and FDB drug (ide, an exact match is performed. If you ('the fields below. Note that at least one fi	pairs based on the info enter description value: ield must be specified.	rmation provided in the forr ३ against Drug A, Drug B, a,	n below. If you ente nd/or Interaction, re	r numeric values against DrugA, DrugB, ecords that contain the given description
Drug A (Generic):						
Drug B (Generic):						
Interaction:						
Severity Level Code:						v
Query						
	Home	Advanced Query/Customization	Easy Search	Drug Pair Lookup	<u>Reports</u>	Help
hum						

Figure 7: Drug-Drug Pair Query Window

Drug Pair Lookup

The Drug Pair Lookup page allows users to search for VA custom drug pairs and FDB drug Interaction and/or select a value for Severity Level Code, an exact match is performed. If ye anywhere in the specified field will be returned.

To begin your search for drug pairs, complete any of the fields below. Note that at least one/

Drug A (Generic):	metyrapone oral
Drug B (Generic):	cyproheptadine hcl
Interaction:	
Severity Level Code:	
Query	
	ome Advanced Query/Customization

Figure 8: Sample Query

VA Tables	Results				
Select	Interaction Description	Routed Generic #1 Description	Routed Generic #2 Description	Action Status	Severity Level Code
Active	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL/LYSINE/VITAMIN B COMPLEX/ZINC ORAL	New	3
Active	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL/LYSINE/VITAMIN B COMPLEX/ZINC ORAL	New	1
Active	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL MISCELLANEOUS	Reviewed	2
Active	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL/VITAMIN B COMPLEX ORAL	New	2
Active	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL ORAL	New	2
<	ii.				>
FDB Tables	Results				
Select	Interaction Description	Routed Generic #1 Description	Routed Generic #2 Description	Severity Level Code	Interaction ID
Open	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL/VITAMIN B COMPLEX ORAL	2	234
Open	METYRAPONEJCYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL ORAL	2	234
Open	METYRAPONE/CYPROHEPTADINE	METYRAPONE ORAL	CYPROHEPTADINE HCL/LYSINE/VITAMIN B COMPLEX/ZINC ORAL	2	234
Open	METVRAPOAICIONER		CYPROHEPTADINE HCL MISCELLANEOUS	2	234

Figure 9: Drug Pair Query Result

You can move the columns in these tables and compare different fields side-by-side. Click the heading and drag and drop it:

A Tables Results			"Request Assigned To" column		
ction Status	Request Submitted By	Action Date	Action Performed By	Request Assigned To	Interaction ID
lodified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476
odified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476
odified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476
odified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476

Figure 10: Default Position of "Request Assigned To"

VA Tables Results		"Request Assigned To" moved	' column		
Action Status	Request Assigned To	 Request Submitted By	Action Date	Action Performed By	Interaction ID
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476

Figure 11: Re-positioned "Request Assigned To" Column

Advanced Query/Customization Page

The Advanced Query / Customization page is used to access customization records from either the FDB Standard table, the VA Custom tables, or both at the same time. This allows you to research existing records, make customizations, or export data.

Accessing the Advanced Query/Customization Page

The Advanced Query/Customization page allows you to retrieve records from either the FDB standard tables, custom tables, or both to research, make customization changes, or export data. The Advanced Query / Customization page can is accessed in one of two ways.

• Click the Advanced Query/Customization tab on the navigation bar near the top of the page. This will open a blank query.



Figure 12: Accessing the Advanced Query / Customization Page

• Click a link from one of the summary tables displayed within the panels on the Home tab. This will generate a query appropriate to the context of the link that was clicked. In the example below, a query displaying criteria to display the New Drug-Drug Interaction records will be displayed.

	HARMACY	NTERPRISE	
FEC2	USTOMIZAT	ION SYSTEM	
Home Advanced Query/C	ustomization	Easy Search	Drug
_			
Last update to First DataBank D	IF database occu	rred on: 05-18-2	012 ver
_ast update to First DataBank D _ast customization update file cr	IF database occu reation occurred (rred on: 05-18-2 on: 05-15-2012	012 ver
Last update to First DataBank D Last customization update file cr My Request History	IF database occu reation occurred (rred on: 05-18-2 on: 05-15-2012	:012 ver
Last update to First DataBank D Last customization update file ci My Request History	IF database occu reation occurred (rred on: 05-18-2 on: 05-15-2012	:012 ver
Last update to First DataBank D Last customization update file ci My Request History Concept	IF database occu reation occurred of	rred on: 05-18-2 on: 05-15-2012 Modified	012 ver
Last update to First DataBank D Last customization update file of My Request History Concept Drug-Drug Interaction	IF database occur reation occurred o New 23	med on: 05-18-2 on: 05-15-2012 Modified 4	2012 ver Revi
ast update to First DataBank D ast customization update file of My Request History Concept Drug-Drug Interaction Professional Monograph	IF database occured of the second sec	rred on: 05-18-2 on: 05-15-2012 Modified 4 0	2012 ver Revi 2 1
ast update to First DataBank D ast customization update file of My Request History Concept Drug-Drug Interaction Professional Monograph Duplicate Therapy	IF database occu reation occurred (New 23 5 2 2 3 2 3	rred on: 05-18-2 on: 05-15-2012 Modified 4 0 0	012 ver Revi 1 6

Figure 13: Access Advanced Query/Customization from the Home Tab
The Query Builder Panel

The Query Builder Panel on the Advanced Query/Customization page allows you to retrieve a specified set of records the VA Custom Tables, the FDB standard tables or Both in order to perform research, make customization changes, or export data. You can use it to create a new query, load a query you have previously saved, or load a query saved by another user.

How to Build a Query

This is the Query Builder page, described above. From this page you can build your own query, run it, save it, run a saved query, or run another user's saved query.

To create a query

1. On the Advanced Query/Customization tab, select a Concept.

Build a Query		
Calact Cancant		
Select Concept		
	Drug-Drug Interaction	
D	Drug Pair	
Run a Saved	Professional Monograph®	
	Duplicate Therapy	
My Queries	Dose Range	

2. Select what data you want to view-- VA, FDB, or Both.

Select VA, FDB, or Both	•
	VA records
	FDB records

3. In the "Enter a value to build a query" area, select the Field you want to use as a query criteria. The available field options will be determined by the Concept you selected earlier.

Enter a value to build a query Fields
Concept Type
Concept ID Number
Concept ID Description
Action Status
Age Low In Days
HITTYPE
Age High In Days
Dose Route
Dase Deute Description

4. Select the Filter you want to impose on the Field.

	Filter	
	Greater than 🔹	
	Contains	
	Equal to	
	Less than or Equal to	
ļ	Greater than or Equal to	
	Begins with	2
ļ	Ends with	עי
	Greater than	
	Less than 😼	
	Not Equal to	

5. Enter a Value to use as your query criteria. The Value must be appropriate for the Field and Filter or an error will be generated. See Query Specifics for additional information.

Value			
6	3		

6. To add additional criteria to the query, make a selection from the And/Or list.



- AND indicates the results must match the new criteria and all the AND-connected criteria above it
- OR indicates that the results must match either the new criteria or the AND-connected criteria above it. See And/Or Usage Examples for additional information.
- 7. To include Historical Records in the query, select the Include Historical Records check box.

- 8. When all criteria have been added, click the Query button. The results will display below the query panel.
- 9. To see details of the record, click the link in the Select column.

Export			
Select	Concept Type	Concept ID Number	Concept ID D
Active	6	15532	BCG LIVE IN (SDV,MDV OF
Active	6	22222222	
Historical	6	476	NITROGLYCI TABLET,SUB
Historical	6	1234	POTASSIUM BICARBONA CITRATE/CIT

And/Or Usage Example

To see approved records with an interaction description equal to "anti" or "Lido", build the query as follows:

Field	Filter	Value	And/Or
Interaction description	Equals	anti	And
Status	Equals	approved	Or
Interaction description	Equals	Lido	And
Status	Equals	approved	

If you build the query below, you will get approved records with an interaction description = "Anti", but you will get all records with an interaction description of "Lido", regardless of status.

Field	Filter	Value	And/Or
Interaction description	Equals	anti	And
Status	Equals	approved	Or
Interaction description	Equals	Lido	

Query Specifics

- Use the YYYY-MM-DD date format for searching date fields within a query
- Date values can only use the following filters::
 - o Equal to
 - Less than or Equal to
 - o Greater than or Equal to
 - o Greater than
 - o Less than

Save a Query

PECS allows you to save a complete query so that you and other PECS users can run a specific query without having to re-build it every time. This feature is not available to users with the Requestor role. Note: the state of the Historical Records check box will not be saved with the query; if desired, it must be re-selected after the query is loaded at run-time.

To save a query

- 1. Create a query in the Build A Query panel. See Build A Query for additional information.
- 2. Enter a name for the query in the Query Name field. The name must contain at least five characters and cannot be longer than 64 characters.
- 3. Click Save Query.

Query Name:	
Concept 6 - Rejected	Save Query
	d'h

4. The saved query will appear in the My Queries list.



Run a Saved Query

PECS allows you to run a previously saved query with the same Concept and content (VA, FDB, or Both). You can run queries that you have saved or those that other users have saved.

To run a saved query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select either My Queries or Other Users's Queries, then select the query you want to run.

4. Click the Load button. This will add the components of the saved query to the Build a Query panel.

My (Queries Other Users' Queries
۲	Concept 6 - Rejected
\bigcirc	Dose Route Not ORAL
\bigcirc	Dose Route Not ORAL, Rejected, Deleted
\bigcirc	Concept6, Powder, Elixir
\bigcirc	Approver 2 Requests Not Assigned
\bigcirc	Aspirin DRC

5. Click the Query button to run the query. You may also select additional criteria to alter or enhance the saved query.

Delete a Saved Query

You can delete queries you have created and saved. Note that the delete operation is immediate; you will not be warned that the query is about to be deleted and there is no undo option.

To delete a Saved Query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select My Queries; you cannot delete a query that was created by another user, then select the query you want to delete.
- 4. Click the Delete button. The query is deleted.

Rename a Saved Query

A saved query can be renamed by loading it then adding a different name in the Query Name field.

To rename a saved query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select My Queries; you cannot rename a saved query created by another user.
- 4. Enter a new the Query Name field.
- 5. Click Save Query. The new query name will appear in the My Queries list in place of the original query.

Sort Query Results

You can change the sort order of results of your query by clicking on the column headings in the display grid. Clicking once will display the records in ascending order (A to Z, 1-2-3 etc.) based on the contents of the column of the header you clicked; clicking a second time display the records in descending order (Z to A, 3-2-1, etc.). A small arrow indicates the direction of the current sort.

Action Performed By	Action Date	Reference Text
SIX_APPROVER	2012-05-10 13:39:25	Sort Direction
SIX_APPROVER	2012-05-10 13:30:32	Indicator
TWO_APPROVER	2012-05-10 13:12:57	
TWO_APPROVER	2012-05-10 13:09:47	
SIX_APPROVER	2012-05-10 10:38:44	
SIX_APPROVER	2012-05-10 10:35:22	
FOUR_APPROVER	2012-05-09 17:35:26	
TWO_APPROVER	2012-05-03 16:00:44	
		• • • • • • • • • • • • • • • • • • •

Figure 14: Sorting Query Results

For VA records, the default sort order is by the 'Action Date' value, from newest to oldest. This puts the VA Customizations that have been updated most recently at the top of the returned list. By default, FDB records are displayed in the order they appeared in the update file sent by FDB. However, they can be resorted by clicking a column header.

Note: Due to technical database restrictions, not all fields can be used to determine the sort order. For example, Concept ID Description on a Dose Range query cannot be used to sort the query results. Clicking these columns will have no result and the current sort order will be retained.

Export Query Results

Query results for both VA and FDB records can be exported to an Excel spreadsheet file.

To export the query results

1. On the appropriate query results panel, click the Export button.

VA Tables	Results	
Export	Concept Type	Concept
Active	6	15532
Active	6	22222222

- 2. Select one of the following options from the dialog box:
 - Click Open to open the exported query in Excel.
 - Click Save to save the exported query to a location on your hard drive.
 - Click Cancel to abandon the export operation.

Query Errors

Running a query will sometimes return an error message.



Figure 15: Query Error Message

In many cases, the error is caused by the query returning too many results which causes the database to time-out. Try re-writing the query with more specific criteria. For example, enter "Aspirin" as the Concept ID Description in a Dose Range query instead of "a" as the Concept ID Description. This will reduce the number of results and potentially prevent database time-outs. Rule of thumb: always be as specific as possible when creating a query.

An error may also appear if the selected Filter is not appropriate for the data type.

Add Default DRC Query

If you are performing a Dose Range Query, there is a special button that displays only on the Dose Range Query window for VA, FDB, or Both. It is a pre-defined search that enters a default Dose Range query. If you do not want to run the default, you can enter specific values yourself, then run your query.

Here are the predefined fields for this Dose Range Query:

- Concept type = 6 and
- AGEHIGHINDAYS >= (greater than or equal to) 6570

To run this query, simply press the Add Default DRC Query, then press Query. The results are shown below:



Figure 16: Default Dose Range Query Window

A Table	s Results					
elect	Concept Type	Concept ID Number	Concept ID Description	Action Status	Age Low In Days	1
<u>.ctive</u>	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Delete Reviewed	30	E
<u>listorical</u>	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Approved	30	
<u>listorical</u>	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Reviewed	30	
listorical III	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	New	30	-
iistorical III FDB Tabl	6 les Results	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	New	30	-
istorical III DB Tabl	6 les Results	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	New	30	4
Export elect	6 les Results Concept Type	63438 Concept ID Number	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description	Age Low In Days	30	F A
iistorical IIII DB Tabl Export elect Ipen	6 les Results Concept Type 5	63438 Concept ID Number 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	Age Low in Days	30 HITTYPE 3	
istorical DB Table Export elect pen pen	6 les Results Concept Type 5 5	63438 Concept ID Number 1049183 1049183	CALCIUM CARGONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726	30 HITTYPE 3 3	, ,
Export elect pen pen	6 les Results Concept Type 5 5 5	63438 Concept ID Number 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-187 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	New Age Low In Days 6570 23726 4745	30 HITTYPE 3 3 1	, ,
Export elect pen pen pen	6 les Results Concept Type 5 5 5 5 5 5	63438 Concept ID Number 1049183 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	New Age Low In Days 6570 23726 4745 4745	30 HITTYPE 3 3 1 1 1	, , (E)
Export DB Table Export elect upen upen upen	6 les Results Concept Type 5 5 5 5 5 5 5 5	63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183	CALCIUM CARGONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 0	30 HITTYPE 3 3 1 1 1 1	
Export elect pen pen pen pen pen pen	6 les Results Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0	30 HITTYPE 3 3 1 1 1 1 1 1 1	, ,
Export elect pen pen pen pen pen pen	6 les Results 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low in Days 6570 23726 4745 4745 0 0 180	30 HITTYPE 3 3 3 1 1 1 1 1 1 1 1 1 1	,
Export elect pen pen pen pen pen pen pen pen pen pen	6 les Results 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 180	30 HITTYPE 3 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, ,
tistorical	6 les Results Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CALCIUM CARGONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 0 180 180 385	30 HITTYPE 3 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, ,
Aistorical FDB Table Export Select Open Open Open Open Open Open Open Open Open	6 EConcept Type 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CALCIUM CARGONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 0 180 180 180 385 385	30 HITTYPE 3 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, ,
Historical Export Helect Deen Deen Deen Deen Deen Deen Deen Deen Deen Deen	6 Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5	63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CALCIUM CARGONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	New Age Low In Days 6570 23726 4745 0 0 180 3865 3657 1460	30 HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, , , , , , , , , , , , , , , , , , ,
distorical (Internet internet	6 Concept Type 5	63438 Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	New Age Low In Days 6570 23726 4745 0 0 180 385 365 365 1460	30 HITTYPE 3 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, , , , , ,

Figure 17: Results from Building a Dose Range Query with Default DRC Query

•

History of Changes

Whenever changes occur to any of the Customization requests (Duplicate Therapy, Professional Monograph, Dose Range, or Drug-Drug Interaction), it can be important to know what those changes are at a glance. You can see these changes in the detail page of each of the concepts. The Drug-Drug Interaction detail page is shown below, but the view is virtually identical in all the concepts with, of course, the relevant fields for that particular concept identified. See the list of relevant fields in the Customization concepts Drug-Drug Interaction Detail, Professional Monograph, Duplicate Therapy Detail, and Dose Range.



Figure 18: History of Changes On-Screen Table

The History of Changes is displayed in two ways: on-screen, via an on-screen table that is displayed interactively above an icon that displays over the name of the required field that has been changed (see screen shot above), and via the History of Changes Report. On the on-screen table, for all concepts, only required fields are reported upon.

The on-screen table that displays the History of Changes shows a quick snapshot of the record's history. It shows the changes that occurred during a record's life between important baselines - FDB/New. Approved, and Deleted. However, the on-screen view displays only the changes that occurred during a milestone, e.g., from New to Approved, or from Approved to Deleted. To view ALL the historical changes a record has incurred on the reportable fields, the user needs to access the History of Changes Report.

In the History of Changes Report, all editable fields, with a couple of exceptions, are reported upon. Note that Current Action Reason, though a required field, is never reported upon in the report nor on the on-screen table.

The image below is a partial image of the FDB Comparison Report for Drug-Drug Interaction. All changes are shown in red.

A	8	6	0	E .	· · · · · · · · · · · · · · · · · · ·	0	n
FDB Update Received:	20120525					Note: * indicates changed FDB data	
And the second se	Action Status	Action Date	DATUP will delete	VA Interaction ID	FDB Interaction ID	Interaction Description	Monograph ID
FDB Before Update					237	ERGOT ALKALOIDS/NITRATES	Ergot Alkaloids/Nitrates - 237
VA Custom	Deleted	2010-05-05		2012742	1274	STEROIDAL CONTRACEPTIVES/APREPITANT	Steroidal Contraceptives/Aprepitant - 1274
EDB After Update			Yes	603ACTE	1274		and a second and a second second second
FDB Before Update					1274	STEROIDAL CONTRACEPTIVES/APREPITANT	Steroidal Contraceptives/Aprepitant - 1274
MA Custom	Not customized						
CDR After Hedate	Not customized		Var		451		
FDB After Opdate			res		451	THEODING HARE (TACOINE	Theorehullings/Tassing 451
FDB Before Opdate					451	THEOPHYLLINES/TACKINE	Theophyllines/Tachne - 451
VA Custom	Not customized						
FDB After Update			Yes		452		
FDB Before Update					452	CYCLOSPORINE/BARBITURATES	Cyclosporine/Barbiturates - 452
VA Custom	Not customized						
FDB After Update			Yes		31860		
FDB Before Update					31860	QUININE/ANTICOAGULANTS	Anticoagulants/Quinine - 140
VA Custom	Not customized						1
FDB After Update			Yes		31585		
FDB Before Update					31585	SFLECTED MACROLIDE ANTIBIOTICS/PIMOZIDE	Pimozide/Selected Macrolide Antibiotics - 415
VA Custom	Not customized					v	
EDB After Undate	Not costoningeo				1623	POSACONAZOLE/CIMETIDINE-HL*	Theophyllines/Ouinclones - 191 *
FDB Before Update					1623	POSACONAZOLE/CIMETIDINE *	Posaconazole/Cimetidine - 1623 *
VA Custom	Rejected	2010-05-17		2015651	1565	RANOLAZINE/QT PROLONGING AGENTS	Ranolazine/QT Prolonging Agents - 1565
VA Custom	Rejected	2010-05-17		2015652	1565	RANOLAZINE/QT PROLONGING AGENTS	Ranolazine/QI Protonging Agents - 1565
FDB After Update					1565	RANOLAZINE/QT PROLONGING AGENTS-TODAY*	Ranolazine/QT Prolonging Agents - 1565
FUB before Opdate					1565	INNIULALINE/QI PROLONOING MOENTS	kanolazme/ di Protonging Agents - 1965
VA Custom	Rejected	2010-05-04		2019797	1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhib
VA Custom	Approved	2010-05-04		2011561	1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhib
FDB After Update					1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhi
FDB Before Update					1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inh
VA Custom	Modified	2012-03-09		2020866	1581	DROSPIRENONE/ACE INHIBITORS; ARBS	Drospirenone/Ace Inhibitors; ARBs - 1581
FDB After Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS	Cyclosporine/Calcium Channel Blockers - 258 *
FDB Before Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS	Drospirenone/Ace Inhibitors; ARBs - 1581 *
VA Custom	New	2012-03-09		2020864	30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)	Eplerenone/Selected Macrolide Antibiotics (mono dele
11000				2020865	30786	SELECTED MACROLID	Eplerenone/Selected Macrolide Antibiotics (mono delet

Figure 19: Changes Shown in FDB Comparison Report

Note: In the Dose Range concept, FDB records cannot be obtained after Customizations are made. Therefore, any History of Changes will not display the original FDB value. (This page included for two-sided copying.)

Modifying Records

Following are example Dose Range, Professional Monographs, Duplicate Therapy, and Drug-Drug Interaction records, shown in Read-Only mode, which is the default view. You can modify these records only if:

- 1. You have the correct security permissions.
- 2. You have clicked the Edit button to bring up the record in Edit mode.
- 3. No other user is modifying the record at the same time (you will be notified if that is the case).

Note that shaded fields on any the detail pages in Edit mode cannot be modified.

Dose Range

Click the Edit Button to open the fields to edit the record. The view below is Read-Only.

	WINTED STATES DEPARTMENT OF VETERAN PECS PHARM CUSTO Home Advanced QueryiCustomiz	S AFFAIRS HACY ENTERPRISE MIZATION SYSTEM ation Easy Search Drug Pair Lookup Reports Help	Welcome, TWO_APPF	ROVER <u>Loqout</u>
	Dose Range			Page Help
• •	To update this record click on the edit bu	tton below.		
	Edit		History	Print Page
	Concept Type	5		
	Concept ID Number (Required)	59940		
	Concept ID Description	MORPHINE SULFATE/DEXTROSE 5%-WATER/PF INTRAVENOUS PLASTIC BAG.INJECTION 100 MG/100 MI	(1 MG/HL)	
	Action Status	New		
	Age Low in Days (Required)	23725		
	Age High In Days (Required)	40150		
	Dose Route (Required)	079 - SUBCUTANEOUS		
	Dose Type (Required)	02 - MAINTENANCE		
	FDBDX	999		
1		4892		

Figure 20: Dose Range Record - Read-Only

Professional Monograph

During customization, you can edit the professional monograph that is displayed. Below is an example in read-only mode. Click the Edit button to modify.

WINTED STATES DEPARTMENT OF VETERA PECS PHAR CUST Home Advanced Query/Custon	INS AFFAIRS IMACY ENTERPRISE OMIZATION SYSTEM Nization Easy Search Drug Pair Lookup Reports Help	Welcome, TWO_APP	PROVER <u>Loqout</u>
Professional Monograph			Page Help
To update this record click on the edit	button below.		
Edit		History	Print Page
Monograph Title (Required)	Digitalis Glycosides/Kaluretics		
Monograph ID	151280		
Action Status	Rejected		
Action Date	2012-05-03 15:07:11		
Action Performed By	TWO_APPROVER		
Action Effective Date			
Corresponding FDB Monograph ID	75		
RequestAssigned To	UNASSIGNED		
Request Submitted By	TWO_APPROVER		
Severity Level (Required) 🕙	3-Moderate Interaction		
Mechanism Of Action	Potassium-losing diuretics may result in potassium depletion which can p tomicity.	predispose patients to digit	alis
Clinical Effects (Required)	May observe increased arrhythmias, resulting from an increase in the car nauses, vomiting, headache, fatig	rdiac response to digitalis. gue, malaise, drowsiness, gen	Symptoms of meralized

Figure 21: Professional Monograph Record- Read Only

Duplicate Therapy

Click the Edit button to modify the record.

WINTED STATES DEPARTMENT OF VETERAN PECS PHARM USSIC Home Advanced Query/Custom	AS AFFAIRS MACY ENTERPRISE MIZATION SYSTEM zation Easy Search Drug Pair Lookup Reports Help	Welcome, TWO_APP	ROVER <u>Loqout</u>
Duplicate Therapy			Page Help
To update this record click on the edit b	utton below.		
Edit		History	Print Page
DTCID	299		
Custom Dup Allowance (Required)	0		
Description (Required)	Osmotic Diuretics		
Action Status	Reviewed		
Action Date	2011-11-08 13:18:52		
Action Effective Date	2011-11-08 13:18:52		
Action Performed By	THREE_APPROVER		
Request Assigned To	TWO_APPROVER		
Request Submitted By	TW0_APPROVER		
Action Reason History	2011/11/08 13:15:51 THREE_APPROVER: submit as reviewed 2011/11/08 13:13:01 TWO_APPROVER: customize		

Figure 22: Duplicate Therapy Record - Read-Only

Drug-Drug Interaction

The Drug-Drug Interaction Panel can be edited only if you have the proper authority and after you click the Edit button.

DEPARTMENT OF VETERAL DEPARTMENT OF VETERAL PECS PHAR CUSTO Home Advanced Query/Custom	NS AFFAIRS MACY ENTERPRISE DMIZATION SYSTEM ization Easy Search Drug Pair Lookup Reports Help		Welcome, TWO_APPROVER Logout
Drug-Drug Interaction			Page Help
 To update this record click on the edit to 	button below.		
Edit Drug Pairs			History Print Page
Informational Messages:			
Following additional VA custom reco	ord(s) exist for the corresponding FDB Drug-Drug Interaction.		
Interaction Type In	teraction ID Interaction Description	Interaction Severity	Interaction Action Status
FDB Interaction 212 VA Interaction 202077	DIGOXIN/VERAPAMIL; MIBEFRADIL DIGOXIN/VERAPAMIL: MIBEFRADIL	2	N/A
Corresponding FDB Interaction ID Interaction Description (Required)	212 DIGOXINVERAPAMIL; MIBEFRADIL		
Monograph ID	Digoxin/Verapamil; Mibefradil - 212		
Action Status	Modified		
Interaction ID	2021519		
Severity Level Code (Required)	2 - Severe Interaction		
Action Date	2012-11-19 16:57:39		
Action Performed By	SIX_APPROVER		
Requester			

Figure 23: Drug-Drug Interaction Panel - Read Only

Single Drug Pair Page Modification Not Allowed

You cannot modify or customize a drug pair if you display a single drug pair from a query on the Drug Pair concept, as shown below:

- 1. Pick the Drug Pair concept, as shown below, and select one of the drug pairs displayed.
- 2. The page that displays is the single drug pair, and an information message is displayed: "Further customization or deletion of this drug pair can be done only through the VA custom Drug-Drug Interaction detail page."

Drug Pairs (Active rea	id-only)
Informational Messages:	
Further customization or	deletion of this drug pair can only be done through the VA custom Drug-Drug Interaction detail page.
Action Status	Approved

3. The easiest way to get to the custom Drug-Drug Interaction detail page is to use the Easy Search tab. See the section "Easy Search Query Page."

Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction

The drug pairs that are associated with a Drug-Drug Interaction (DDI) need to go through the approval/state change process themselves (be approved, rejected, modified, or deleted), separately from the DDI. If the drug pairs are acted upon at the same time as the DDI is acted upon, there is no problem in an approver knowing that the drug pair needs to be acted upon. However, drug pairs may be added or have their status changed even after a DDI has been acted upon. The way an approver will know if they need to act on a drug pair associated with an already-approved DDI is by the row on each of the home page tables that displays "Approved Drug-Drug Interaction with Pending Drug Pairs."

My Assigned Requests for Review

Concept	Awaiting Review
Drug-Drug Interaction	<u>Z</u>
Professional Monograph	4
Duplicate Therapy	3
Dose Range	1
Approved Drug Drug Interactions With Pending Drug Pairs	1

My Assigned Requests for Approval

Concept	Awaiting Approval
Drug-Drug Interaction	1
Professional Monograph	2
Duplicate Therapy	3
Dose Range	0
Approved Drug Drug Interactions With Pending Drug Pairs	0

My Assigned Requests for Deletion

Concept	Awaiting Deletion
Drug-Drug Interaction	0
Professional Monograph	0
Duplicate Therapy	0
Dose Range	1
Approved Drug Drug Interactions With Pending Drug Pairs	1

Figure 24: Home Page with Approved DDIs with Pending Drug Pairs

On the screen above in the application, if you select the link "My Assigned Drug Pairs Associated with Approved Drug-Drug Interactions" for one of the states listed that has actual counts (not zero), you are taken to the Advanced Query/Customization page, shown below, that displays the results for all approved Drug-Drug Interactions with associated Drug Pairs assigned to you in that state.

VA Tables	Results		
Export			
Select	Corresponding FDB Interaction ID	Interaction Description	Monograph ID
<u>Active</u>	2177	CITALOPRAM/CYP2C19 INHIBITORS	2177

Figure 25: My Assigned DDIs with Pending Drug Pairs List

Drug Pair Customization

The Drug Pair Customization page allows users to create or delete drug pairs associated with the VA Customized Drug-Drug interaction as well as perform mass VA Workflow updates to all associated Drug Pairs. To reach this page, the user must click the 'Drug Pairs' button on a VA customized Drug-Drug interaction detail page:

Me Advanced Query/Custor g-Drug Interaction Indate this record click on the edit	nization Easy Search D	rug Pair Lookup Reports Help		
ug-Drug Interaction				
update this record click on the edit	houten hatau			Page He
	button below.			
dit Drug Pairs				Print Page
ormational Messages:				
The associated drug pairs are not Following additional VA custom re	all reviewed yet. To submit this in cord(s) exist for the correspondin	nteraction as reviewed, you must review all ass	ociated drug pairs. First click on the Drug P	airs button and then, take appropriate action.
Interaction Type Inte	raction ID	Interaction Description	Interaction Severity	Interaction Action Status
DB Interaction 45	AMINOGLYCOSI	DES/PENICILLINS	3	N/A
Interaction 202073	Z AMINOGLYCSSI	DES/PENICILLINS	1	Approved
Interaction 202078	5 AMINOGLYCOSI	DES/PENICILLINS	3	New
A Interaction 202073	AMINOGLYCOSI	DES/PENICILLINS	2	Approved
A Interaction 202088	AMINOGLYCOSI	DES/PENIOLLINS	9	New
eraction Description (Required)	VA Custom AMINOGLYCOSI	DES/PENICILLINS	1	Approved
teraction Description (Required) phograph ID	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins	- 45 Here is one of the D was selected from t	rug-Drug Interactions that	Approved
teraction Description (Required) onograph ID tion Status orresponding FDB Interaction ID	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45	DES/PENICILLINS	rug-Drug Interactions that he list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug	Approved
eraction Description (Required) onograph ID. tion Status presponding FDB Interaction ID. eraction ID.	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738	Here is one of the D was selected from t with Pending Drn otherwise act on the Pair	rug-Drug Interactions that the list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
eraction Description (Required) anograph ID tion Status presponding FDB Interaction ID teraction ID everity Level Code (Required)	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738 2 - Severe Interaction	Here is one of the D was selected from t with Pending Drn otherwise act on the Pair	rug-Drug Interactions that the list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
teraction Description (Required) anograph ID_ tion Status orresponding FDB Interaction ID_ teraction ID everity Level Code (Required) tion Date	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738 2 - Severe Interaction 2012-02-23 12:52:05	Here is one of the D was selected from t with Pending Dru otherwise act on the Pair	rug-Drug Interactions that the list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
eraction Description (Required) anograph ID. tion Status presponding FDB Interaction ID. eraction ID (everity Level Code (Required) tion Date tion Performed By	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738 2 - Severe Interaction 2012-02-23 12:52:05 ONE_APPROVER	Here is one of the D was selected from t with Pending Dru otherwise act on the Pair	rug-Drug Interactions that the list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
eraction Description (Required) anograph ID. tion Status presponding FDB Interaction ID eraction ID everity Level Code (Required) tion Date tion Performed By equest Submitted By	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738 2 - Severe Interaction 2012-02-23 12:52:05 ONE_APPROVER FIVE_APPROVER	Here is one of the D was selected from t with Pending Dru otherwise act on the Pair	rug-Drug Interactions that the list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
teraction Description (Required) onograph ID. ction Status orresponding FDB Interaction ID teraction ID exertly Level Code (Required) ction Date ction Performed By equest Submitted By ction Effective Date	VA Custom AMINOGLYCOSI Aminoglycosides/PenicIIIins Approved 45 2020738 2 - Severe Interaction 2012-02-23 12:52:05 ONE_APPROVER FIVE_APPROVER 2012-02-23 12:52:05	Here is one of the D was selected from t with Pending Dr otherwise act on the Pair	rug-Drug Interactions that he list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved
teraction Description (Required) onoaraph ID. :tion Status orresponding FDB Interaction ID teraction ID everity Level Code (Required) :tion Date :tion Performed By aquest Submitted By tion Effective Date aquest Assigned To	VA Custom AMINOGLYCOSI Aminoglycosides/Penicillins Approved 45 2020738 2 - Severe Interaction 2012-02-23 12:52:05 ONE_APPROVER FIVE_APPROVER 2012-02-23 12:52:05 UNASSIGNED	IDES/PENICILLINS - 45 Here is one of the D was selected from t with Pending Dr otherwise act on the Pair	rug-Drug Interactions that he list of Approved DDIs ug Pairs. To review or drug pairs, click the Drug rs button.	Approved



After you click the Drug Pairs button, you see a window similar to the one below. After you click the Edit button, you can act on the drug pairs.

	air Cua	tomization									Deere
ncel f	Edit	SUTHIZATION									Page
Inter	raction 1	Type Inter 2020738	action ID VA Custom	Interaction Descrip	ition			Interacti	on Severity	Interactio	n Action Status
8 Intera	action	<u>45</u>	AMINOGLY	COSIDES/PENICILLINS				3	1	N/A	
er Exis Inte	sting VA (Custom Record(s) Type Inte	eraction ID	Interaction Descript	tion			Interaction	Severity	Interaction	Action Status
Interac Interac Interac Interac	ction ction ction ction	202073 202078 202078 202078	AMINOGI 35 AMINOGI 39 AMINOGI 30 AMINOGI	LYCOSIDES/PENICILLINS LYCOSIDES/PENICILLINS LYCOSIDES/PENICILLINS			1 3 2 9		Ap Ni Ap	pproved ew pproved ew	
nterac	ction	202000	AMINOGL	LYCOSIDES/PENICILLINS - Test 1			1		Ap	pproved	
N	g Pairs	MOL	DIFIED	REVIEWED		APPROVE	ED		DELETE REV	/IEWED	
Nect A	g Pairs	MOE Routed Generic #1 Description	DIFIED Routed Generic #2	REVIEWED Interaction Description	Severity Level	APPROVI Severity Level	ED Interaction	Corresponding FDB	DELETE REV	/IEWED	Action Perform
] N ect Ar	g Pairs	Routed Generic #1 Description	Routed Generic #2 Description ABOBOTULINUMTOXINA INTRAMUSCULAR	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code	APPROVE Severity Level Description Severe Interaction	ED Interaction ID 2020738	Corresponding FDB Interaction ID 45	DELETE REV Request Submitted By	Request Assigned To	Action Perform By R FIVE_APPROVI
] N ect Sta	g Pairs	MOE Routed Generic #1 Description ACACIA ORAL STREPTOMYCIN SULFATE NITRANUSCULAR	Routed Generic #2 Description ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code 2	APPROVI Severity Level Description Severe Interaction Severe Interaction	ED Interaction ID 2020738 2020738	Corresponding FDB Interaction ID 45 45	DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER	Request Assigned To R FIVE_APPROVER	Action Perform By R FIVE_APPROVI ONE_APPROV
Net Sta	g Pairs	MOL Routed Generic #11 Description ACACIA ORAL STREPTOMYCIN SULFATE INTRAINUSCULAR 1.2- PENTANEDIOL MISCELLANEOUS	ABOBOTULINUMTOXINA ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code 2 2	APPROVI Severity Level Description Severe Interaction Severe Interaction	ED Interaction 10 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45	DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To R FIVE_APPROVER	Action Perform By R FIVE_APPROVI ONE_APPROVI R FIVE_APPROVI
] N ect Ar Ne App	g Pairs	MOD MOD Routed Generic #1 Description ACACIA ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR	ABOBOTULINUMTOXINA ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS 1.3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code 2 2 2 2 2	APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction	ED Interaction 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45	DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To R FIVE_APPROVER	Action Perform By R FIVE_APPROVI ONE_APPROVI ONE_APPROVI ONE_APPROV
 N April April April April Ne Ne 	g Pairs	MOE Routed Generic #11 Description ACACIA ORAL STREPTOMYCIN SULFATE PENTANEDIOL MISCELLANEOUS STREPTOMYCIN SULFATE NTRANUSCULAR STREPTOMYCIN SULFATE MISCELLANEOUS	ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS 1.3-BUTANEDIOL MISCELLANEOUS SODIUMDEXTROSE 5%-WATER SODIUMDEXTROSE 5%-WATER SODIUMDEXTROSE 5%-WATER	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Image: Severity Level Code 2 2 2 2 2 2 2 2	APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction	ED Interaction 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45	DELETE REV DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER REVE_APPROVER	Action Perform By R FIVE_APPROVI ONE_APPROVI R FIVE_APPROVI ONE_APPROVI R FIVE_APPROVI
App Ne Ne	g Pairs	MOD MOD Routed Generic #1 Description ACACIA ORAL STREPTOMYCIN SULFATE NITRAMUSCULAR I.2- PENTANEDIOL MISCELLANEOUS STREPTOMYCIN SULFATE MISCELLANEOUS PAROMOMYCIN	ABOBOTULINUMTOXINA INTRAMUSCULAR ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS SODIUMDEXTROSE 5%-WATER SODIUMDEXTROSE 5%-WATER INTRAVENOUS PIPERACII IN	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	V Severity Level Code 2	APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction Severe Severe Severe Severe	ED Interaction 2020738 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45 45	DELETE REV Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX APPROVER	Request Assigned To FIVE_APPROVER	Action Perform By R FIVE_APPROVI ONE_APPROVI ONE_APPROVI ONE_APPROVI R FIVE_APPROVI SIX APPROVI
Ne App	g Pairs	MOL Routed Generic #1 Description ACACIA ORAL STREPTOMYCIN SULFATE INTRANUSCULAR 1.2- PENTANGUIAN SULFATE INTRANUSCULAR SULFATE INTRANUSCULAR SULFATE MISCELLANEOUS SULFATE MISCELLANEOUS PAROMOMYCIN Hect/Deselect AII D	ABOBOTULINUMTOXINA ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS PIPERACII IN INTRAVENOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom VA	Severity Level 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction Severe Interaction Severe	ED Interaction 10 2020738 2020738 2020738 2020738 2020738 2020738 et Record	Corresponding FDB Interaction ID 45 45 45 45 45 45 45 45 45 45 45 45	DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX_APPROVER O 100 Max	Request Assigned To RFIVE_APPROVER RFIVE_APPROVER RFIVE_APPROVER SIX APPROVER X 0 200	Action Perform By R FIVE_APPROVI ONE_APPROVI ONE_APPROVI ONE_APPROVI R FIVE_APPROVI SIX APPROVI SIX APPROVI Max ① A
Ne App Ne Ne	g Pairs	MOE Routed Generic #1 Description ACACIA ORAL STREPTOMYCIN SULFATE NITRANUSCULAR 1.2- PENTANEDIOL MISCELLANEOUS STREPTOMYCIN SULFATE STREPTOMYCIN SULFATE MISCELLANEOUS PAROMOMYCIN lect/Deselect All D guired)	NAPCILLIN SOLUMOEXTROSE SAWATER NAFCILLIN SOLUM NAFCILLIN SOLUM MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE SAWATER NAFCILLIN SODIUMDEXTROSE SAWATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE SAWATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE SAWATER INTRAVENOUS PIPERACII I IN rug Pairs Displayed from	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom VA Cust	Severity Level Code 2 <td>APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction Severe Severe Interaction</td> <td>ED Interaction 2020738 2020738 2020738 2020738 2020738 2020738 et Record</td> <td>Corresponding FDB Interaction ID 45 45 45 45 45 45 45 45 45 45 45</td> <td></td> <td>Assigned To Request Assigned To R FIVE_APPROVER R FIVE_APPROVER R FIVE_APPROVER R X APPROVER X 0 200</td> <td>Action Perform By R FIVE_APPROVI ONE_APPROVI ONE_APPROVI ONE_APPROVI SIX APPROVI SIX APPROVI Max</td>	APPROVI Severity Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction Severe Severe Interaction	ED Interaction 2020738 2020738 2020738 2020738 2020738 2020738 et Record	Corresponding FDB Interaction ID 45 45 45 45 45 45 45 45 45 45 45		Assigned To Request Assigned To R FIVE_APPROVER R FIVE_APPROVER R FIVE_APPROVER R X APPROVER X 0 200	Action Perform By R FIVE_APPROVI ONE_APPROVI ONE_APPROVI ONE_APPROVI SIX APPROVI SIX APPROVI Max

Figure 27: List of Drug Pairs You Can Act On

When you add new drug pairs, they are by default assigned to the same User ID as the associated DDI, but an Approver can reassign the drug pairs.

ome Advanced Query/Customization	TION SYS Easy Sear	FEM ch Drug Pair Lookup Reports Hel	p	
ug Pair Customization				Page He
ncel Edit				
Interaction Type Interaction	ID RIMO		Interaction Severit	Interaction Action Status
3 Interaction 358	PIMO	ZIDE/TRICYCLIC COMPOUNDS	1	N/A
Select Drug Pairs to add to the abov	e VA Custor	n Interaction		
ct Drug Pair(s) Source	0	Existing customized Drug Pairs for this ED	B Drug-Drug Interaction are not displayed	
g pairs norm concesponding r DD interaction a pair from Routed Generic Drug lists		Existing customized brag r and for this r bi	B Brag Brag interaction are not displayed.	
25 % SODIUM CHLORIDE INJECTION	neric #1 Desc	ription	Routed Gen 225 % SODIUM CHLORIDE INJECTION	eric #2 Description
25 % SODIUM CHLORIDE INJECTION	neric #1 Desc	ription	Routed Gen 225 % SODIUM CHLORIDE INJECTION	eric #2 Description
225 % SODIUM CHLORIDE INJECTION	neric #1 Desc Er	ription Iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction.	eric #2 Description
Routed de 225 % SODIUM CHLORIDE INJECTION ference Text (drug pair reference text):	neric #1 Desc	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction.	eric #2 Description
Routed de 225 % SODIUM CHLORIDE INJECTION ference Text (drug pair reference text):	neric #1 Desc	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction.	Inge the assignee for the new
rent Action Reason (for drug pair creation	neric #1 Desc Er 1): (Required,	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	eric #2 Description
rent Action Reason (for drug pair creation	eric #1 Desc Er n): (Required)	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	eric #2 Description
routed de 225 % SODIUM CHLORIDE INJECTION erence Text (drug pair reference text): rent Action Reason (for drug pair creation	eric #1 Desc Er	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	ric #2 Description
routed de 225 % SODIUM CHLORIDE INJECTION erence Text (drug pair reference text): "rent Action Reason (for drug pair creation Hymed To(Required) /E_APPROVER	eric #1 Desc Er	iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	ige the assignee for the new en assigning a new drug pair ed DDI, as the default is the who is assigned the DDI.
routed de 225 % SODIUM CHLORIDE INJECTION erence Text (drug pair reference text): rent Action Reason (for drug pair creation rent Action Reason (for drug pair creation rent Action Reason (for drug pair creation stomize	Er	iption Iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	ige the assignee for the new en assigning a new drug pair ed DDI, as the default is the who is assigned the DDI.
rence Text (drug pair reference text): rent Action Reason (for drug pair creation Hypered To(Required) re_APPROVER stomize Drug Pairs	Er	ription Iter values in text boxes below and click 'Cus	Routed Gen 225 % SODIUM CHLORIDE INJECTION tomize' to add drug pairs to interaction. You can char drug pair whe to an approv same user	ige the assignee for the new en assigning a new drug pair ed DDI, as the default is the who is assigned the DDI.

Figure 28: Assigned To Drop-Down When Adding a Drug Pair

When you are working with the Drug Pair customization window and handling the pending drug pairs, you can use the drop-down to assign the Drug Pairs to a different user. The default is the Approver who is assigned to the DDI, but you can change that.

ıg l	Pair Cu	stomization								Page H
100	el Edit									
Int	teraction	Type Inter	action ID	Interaction Descrip	tion		Interactio	on Severity	Interaction	Action Status
Int	raction teraction	<u>2020738</u> <u>45</u>	AMINOGLYC	AMINOGLYCOSIDES/PENICILLINS COSIDES/PENICILLINS			2 3		Approved N/A	
r E: In	xisting VA	Custom Record(s)	eraction ID	Interaction Descript	tion		Interaction	Severity	Interaction	Action Status
Iter	raction	202073 202073	AMINOGL	YCOSIDES/PENICILLINS		1	moradadi	Ap	pproved	
iter	raction	202073	AMINOGL AMINOGL	YCOSIDES/PENICILLINS		2		Ap	pproved	
iter	raction	202088	0 AMINOGL	YCOSIDES/PENICILLINS YCOSIDES/PENICILLINS - Test 1		9		N Aj	ew pproved	
D	rug Pair:	5								
D	nug Pain	s I Moc	DIFIED	REVIEWED	V APF	PROVED	Ŀ	DELETE REV	/IEWED	
Ct	NEW Action Status	Routed Generic #1 Description ▲	DIFIED Routed Generic #2 Description	REVIEWED Interaction Description	Severity Sever Level Code	PROVED erity vel Interaction ription ID	n Corresponding FDB Interaction ID	DELETE REV Request Submitted By	/IEWED Request Assigned To	Action Perform By
Ct	NEW Action Status New	Routed Generic #1 Description ▲ 1.2- PENTANEDIOL MISCELLANEOUS	Routed Generic #2 Description 1,3-BUTANEDIOL MISCELLANEOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code 2 Sever Descr 2 Sever Intera	PROVED erity vel Interaction ription ID re 2020738 iction	Corresponding FDB Interaction ID 45	DELETE REV Request Submitted By FIVE_APPROVER	Request Assigned To FIVE_APPROVER	Action Perform By FIVE_APPROVI
Ct	NEW Action Status New	Routed Generic #1 Description 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL	NFIED Routed Generic #2 Description 1,3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Image: Severity APF Level Description Level Description 2 Severity 2 Severity 2 Severity	erity vel Interaction ription ID 2020738 cction re re cction 2020738	Corresponding FDB Interaction ID 45 45	DELETE REV Request Submitted By FIVE_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER	Action Perform By FIVE_APPROVI FIVE_APPROVI
Di ct	NEW Action Status New New	Routed Generic #1 Description A 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL	Anticological and a second a seco	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Image: Sevent code Sevent code Sevent code 2 Seven intera Seven intera 2 Seven intera Seven intera 2 Seven intera Seven intera	erity vel Interaction ription ID 2020738 rection 2020738 rection 2020738 construction 2020738	Corresponding FDB Interaction ID 45 45 45	DELETE REV Request submitted By FIVE_APPROVER FIVE_APPROVER SIX_APPROVER	Request Assigned To FIVE_APPROVER SIX_APPROVER	Action Perform By FIVE_APPROVI FIVE_APPROVI SIX_APPROVE
Ct	NEW Action Status New New Approved	Routed Generic #1 Description 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR	Routed Generic #2 Description 1,3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Image: Sevent code APPF Sevent code Descr 2 Sevent interai	PROVED erity vel Interaction ID 2020738 ction 2020738 2020738 ction 2020738 ction 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45	DELETE REV Request Submitted By FIVE_APPROVER FIVE_APPROVER SIX_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER SIX_APPROVER	Action Perform By FIVE_APPROVI FIVE_APPROVI SIX_APPROVE ONE_APPROV
	NEW Action Status New New Approved Approved	Routed Generic #1 Description A 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE	ABOBTULINUMTOXINA NITRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS SODIUMDEXTROSE 5%-WATER INTRAVENOUS		Image: Sevent cool Sevent cool <td>PROVED ription Interaction re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738</td> <td>Corresponding FDB Interaction ID 45 45 45 45 45 45</td> <td>DELETE REV Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER</td> <td>IEWED Request Assigned To FIVE_APPROVER SIX_APPROVER</td> <td>Action Perform By FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV</td>	PROVED ription Interaction re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738 re 2020738	Corresponding FDB Interaction ID 45 45 45 45 45 45	DELETE REV Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	IEWED Request Assigned To FIVE_APPROVER SIX_APPROVER	Action Perform By FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV
	NEW Action Status New New Approved Approved New	Routed Generic #1 Description A 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR	ABOBOTULINUMTOXINA NISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS		Image: Sevent code Sevent code 2 Sevent interar	PROVED erity vel Interaction ID 2020738 cretion 2020738 2020738 cretion 2020738 2020738 cretion 2020758 cre	Corresponding FDB Interaction ID 45 45 45 45 45 45	DELETE REV Comparison of the second	Request Assigned To FIVE_APPROVER SIX_APPROVER	Action Perform By FIVE_APPROVI FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV
Di tt	NEW Action Status New Approved Approved Status Stat	Routed Generic #1 Description	ABOBOTULINUMTOXINA INTRAVENOUS SoluMDEXTROSE S%-WATER INTRAVUSCULAR PIPERACILLIN SODIUMDEXTROSE S%-WATER INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS		Image: Sevent code APPF Level Descr Descr 2 Sevent Intera	PROVED evity vel interaction ID 2020738 cction 2020738 cction 2020738 cction 2020738 cction 2020738 cction 2020738 cction C020738 cction C020738 Cction C020738 Cction C020738 Cction C020738 Cction C020738 Cction Cction C020738 Cction Ccti	Corresponding FDB Interaction ID 45 45 45 45 45 45 45 45 45 45	DELETE REV DELETE REV Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER O 100 Maximum	Request Assigned To FIVE_APPROVER SIX_APPROVER	Action Perform By FIVE_APPROVI FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV FIVE APPROVI FIVE APPROVI
	NEW Action Status New Approved Approved Signed To/Reference Signed To/Reference Signed To/Reference	Routed Generic #1 Description - 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR	ABOBTULINUMTOXINA INTRAVENOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS NAFCILIN SODIUM INTRAVENOUS NAFCILI IN NAFCILI IN NAFCILI IN	REVIEWED Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom VA Cu	Image: Sevent condent	PROVED erity vel Interaction ID 2020738 ction 2020738 c	Corresponding FDB Interaction ID 45 45 45 45 45 45 45 45 45		IEWED Request Assigned To FIVE_APPROVER SIX_APPROVER FIVE APPROVER FIVE APPROVER CO 2001 Coro d	Action Perform By FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV FIVE APPROV FIVE APPROV All

Figure 29: Assigned To Drop Down When Editing Drug Pairs

Note: If you change the state of the drug pairs to Submit as Reviewed or Submit for Delete, the drug pairs are automatically reassigned to the "Unassigned" category.

Also note: If you wish to put a Drug-Drug Interaction (DDI) into the Delete_Reviewed state, the Drug Pairs associated with the DDI must be in either a "Delete Reviewed," "Rejected" or "Deleted" state.

Record Locking Feature

All five concepts available in PECS, Drug-Drug Interaction, Drug Pairs, Professional Monograph, Dose Range, and Duplicate Therapy all have a record locking feature, which means that only a single user can edit a PECS record. Multiple users can no longer simultaneously edit a record. This feature eliminates the possibility that users can overwrite each other's changes and/or omit changes made by another.

For instance, if a user is editing a Drug-Drug Interaction and another user tries to edit the same record, here is the message that is displayed:



Here is the scenario:

- 1. User 1 logs in (e.g., Approver 1).
- 2. User 1 opens an active (not historical) record (in this sample, a Drug-Drug Interaction, but could be any concept) from either their own list or from building a query:

WINTED STATES DEPARTMENT OF VETER	ANS AFFAIRS	the second second		
PECS	RMACY ENTERPRISE TOMIZATION SYSTEM			Welcome, ONE_APPROVER Logout
Drug-Drug Interaction	Readon Casy Search Drug Pail Lookup Re	epons nelp		Page Help
To undate this record click on the edi	t button below			
Edit Drug Pairs				Print Page
Informational Messages:				
 The associated drug pairs are not drug pairs. 	t all approved as yet. To approve the interaction, you mus	t approve all the associated drug pairs	first. Click on the Drug Pairs	button to view and approve the associated
Interaction Type Ir FDB Interaction 112	ANTIDIABETICS, ORAL/SALICYLATES	scription 3 3	Interaction Severity	Interaction Action Status
Interaction Description (Required)	ANTIDIABETICS, ORAL/SALICYLATES			
Monograph ID	Antidiabetics, Oral/Salicylates - 112			
Action Status	New			
Corresponding FDB Interaction ID	112			
Interaction ID	2020881			
Severity Level Code (Required)	3 - Moderate Interaction			
Action Date	2012-03-14 06:42:08			
Action Performed By	FOUR_APPROVER			
Request Submitted By	FOUR_APPROVER			
Action Effective Date				
Request Assigned To	UNASSIGNED			
Clinical Effect Code 1 (Required)	Increased effect of the former drug			
Clinical Effect Code 2				
EDI Number				
EDI Text				1
DI Facts Number				
DI Facts Unset				
DI Facts Severity				
DI Facts Documentation				
DI Facts Text				
Micromedex Severity				
Micromedex Onset				
Micromedex Substantiation				
Micromedex Text				
Medline Hits				
Medline Text				
Package Insert				
- Package Insert Text				
PBM Criteria				
PBM Criteria Text				
AIDS Guidelines				
AIDS Guidelines Text				
Interaction Source				
Interaction Type				
Highest Level of Evidence				
Group Discussion				
Action Reason History	2012/03/14 18:42:08 በWF ΔΡΡΒΟυΨΕΒ· +=>+ M	MC		
	2012/03/14 16:27:06 THREE APPROVER: Test 2012/03/14 14:01:22 FOUR APPROVER: test 2012/03/14 14:00:34 FOUR_APPROVER: creat	: again mmc ng :ing new		
Current Action Reason (Required)				
Edit Drug Pairs				Print Page
	Home Advanced Query/Customization	Easy Search Drug Pair Loo	okup Reports	Help
	Home Advanced Query/Customization	Easy Search Drug Pair Loo	okup <u>Reports</u>	Help

3. User 1 determines they need to make a change to this record. They click the Edit button and the following window displays:

Home Advanced Query/Custom	zation Ea	sy Search Drug Pair L	ookup Reports Help				
rug-Drug Interaction							Page H
ancel Edit							
Interaction Type Inte	raction ID	In	teraction Description	10,000	Interaction Severity		Interaction Action Status
DB Interaction 112		ANTIDIABETICS, ORAL/S	SALICYLATES	3		NIA	
teraction Description (Required)	ANTIDIABE	TICS, ORAL/SALICYLAT	ES				
onograph IO	Antidiabetic	s, Oral/Salicylates - 112					
tion Status	New						
presponding EDB Interaction ID.	112						
eraction ID	2020881						
everity Level Code (Required)	3 - Moderati	e Interaction					2
tion Date	2012-03-14.0	6.42.08					
son Penomied By	FOUR APP	ROVER					
tion Effective Date	roonjarn	NOVER					
rquest Assigned To	UNASSIGN	ED					
inical Effect Code 1 (Required)	Increased e	flect of the former drug					
inical Effect Code 2							v
N Number							~
IV Text							
Facts Number							
Facts Onset							
Facts Seventy							
Facts Documentation							
Facts Text							
someder Genet							
cromeday Substantiation							
cromedex Text							
rdline Hits							•
edline Text							2
							1
ickage Insert							2
ckage Insert Text							1
M Criteria							
M Criteria Text							
S Guidelines							
DS Guidelines Text							
eraction Source							×
eraction Type							~
phest Level of Evidence							
Dep Discussion							
							-
ion Reason History	2012/03/1 2012/03/1 2012/03/1 2012/03/1	4 18:42:08 CNE_APPI 4 16:27:06 THREE_AI 4 14:01:22 FOUR API 4 14:00:34 FOUR API	ROVER: test MMC PPROVER: Test again m PROVER: testing PROVER: creating new	ec.			
rrent Action Reason (Reautined)							
(contrast of contrast of)							
ancel Edit	ved Reje	ct. Modify					

4. At the same time User 2 (e.g., Approver 3) signs into the same record:

WITED STATES		
DECC PHA	ANS AFFAIRS Welcome, THREE_APPROVER Logou	t
	TOMIZATION SYSTEM	
Home Advanced Query/Custo	mization Easy Search Drug Pair Lookup Reports Help	- 1
Drug-Drug Interaction	Page Hi	elp
To update this record click on the edi	t button below.	
Edit Drug Pairs	Print Page	
Informational Messages:		
 The associated drug pairs are not drug pairs. 	t an approved as yet, to approve the interaction, you must approve an the associated drug pairs inst. Citck on the Drug Pairs button to view and approve the associated	
Interaction Type In	nteraction ID Interaction Description Interaction Severity Interaction Action Status	
FDB Interaction 112	ANTIDIABETICS, UKALISALICTLATES 3 INA	
Interaction Description (Required)	ANTIDIABETICS, ORAL/SALICYLATES	
		ł
Monograph ID	Antidiabetics, Oral/Salicylates - 112	
Action Status	New 112	
Interaction ID	2020881	1
Severity Level Code (Required)	3 - Moderate Interaction	4
Action Date	2012-03-14 06:49:24	,
Action Performed By	FOUR_APPROVER	1
Request Submitted By	FOUR_APPROVER	
Action Effective Date		i
Request Assigned To	UNASSIGNED	1
Clinical Effect Code 1 (Required)	Increased effect of the former drug	1
Clinical Effect Code 2		
EDI Number		
EDIText		
DI Facts Number		(
DI Facts Onset		
DI Facts Documentation		-
DI Facts Text		1
Micromedex Severity		
Micromedex Onset		
Micromedex Substantiation		4
Micromedex Text		f
Medline Hits		
Medline Text		ł
Package Insert		
Package Insert Text		
PBM Criteria Text		
AIDS Guidelines		
AIDS Guidelines Text		1
Interaction Source		(
Interaction Type		
Highest Level of Evidence		
Group Discussion		
Action Reason History	2012/03/14 18:49:24 ONE_APPROVER: Test four MMC 2012/03/14 18:42:08 ONE_APPROVER: test MMC 2012/03/14 16:12:7:16 THREE_APPROVER: Test again mmc 2012/03/14 14:01:22 FOUR APPROVER: testing	1
	2012/03/14 14:00:34 FOUR_APPROVER: creating new	
Current Action Reason (Required)		1
Edit Drug Pairs	Print Page	
	Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	
and the second sec	a defined on a set of the set of	

5. User 2 clicks Edit, and the following message displays:



- 6. User 1 makes changes and clicks the Modify button. The record is returned in read-only mode with the changes:
- 7. User 2 waits a few minutes and clicks the Edit button again. They receive this message:

Window	s Internet Explorer 🛛 🔀
1	This Record was recently modified by another user and is no longer current. Click OK to open the current record.
	ОК

User 2 and all users will now be able to access the latest changes that have been made to a customization.

The Record Locking feature has safeguards that prevent a user from keeping a record locked too long; also, if the user leaves the record for any reason without completing the modification, the user is warned that they will lose their changes if they continue to navigate away from the record.

If the user does choose to leave the record without completing and saving their changes, the record is unlocked so others may work on it. If the user does not respond to the warning message, the

Here is another scenario:

- 1. You sign on and run a query for the concept for a customized record you want to modify.
- 2. You find the record and click the Modify button. The record opens in Edit mode and is locked for other users.
- 3. You begin to edit the record and for whatever reason, decide to do any one of the following: click any link on the page (except the help link), click any of the top navigation buttons, or close the browser. You see this message:

Windows	Internet Explorer 🛛 🔀
♪	Are you sure you want to navigate away from this page?
	Press OK to continue, or Cancel to stay on the current page.
	OK Cancel

What this message means is that if you click OK, you will be taken to whatever link you clicked, your changes will be lost, and the record will be unlocked so others may edit it. If you click Cancel, you remain on the record you were editing, in Edit mode and the record remains locked for other users.

4. You continue to edit the record, but end up having to answer several instant messages for 19 minutes. You hear a beep and go back to the PECS window, and see this message:



5. You click OK and continue to edit the record, but are called away. You are called away for 30 minutes. When you return, you see the same message as in Step 4, but this time if you click OK, you are returned to the read-only record, and any changes you made will have been lost.

Note: The same is true if you do not respond to the message that is displayed in Step 3 within 19 minutes. The editing expiration message shown in Step 4 displays, and if you do not click OK within one minute, the record is unlocked. When you return, you must click OK and you are returned to the read-only record.

Creating Multiple VA Custom Drug-Drug Interactions to One FDB Record

You can create multiple VA Custom Drug-Drug Interactions (DDIs) from one corresponding FDB Record. If you open an FDB DDI record on the Advanced Query/Customization page, the DDI Detail page will open. If there are any VA custom records for this FDB DDI, you'll see a message stating that "The following VA custom record(s) already exist for this FDB Drug-Drug Interaction," and a table and a link to any interactions displays. See below:

DECS PHA	ANS AFFAIRS	ERPRISE				Welcome, SIX	_APPROVER Logou
Home Advanced Query/Custo	mization Ea	sy Search Drug Pair Lookup Repo	rts Help				
Prug-Drug Interaction							Page He
undate this record click on the edi	t button below						
dit	bullon below.		Here are t	he Custom Records	s for this		Print Page
			that the in	teraction severity le	vels are		
formational Messages:			different	you cannot have m of the same severit	ore than		
Following VA custom record(s) alr	eady exist for thi	s FDB Drug-Drug Interaction.			3.		
Interaction Type	Interaction ID	Interaction Descri	ption	Interaction S	Severity	Interaction	Action Status
A Interaction 2020 A Interaction 2020	<u>334</u> 957	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS		9	App Nei	w	
A Interaction	<u>660</u>	RASAGILINE/CYP1A2 INHIBITORS		2	Del	lete Reviewed	
teraction Description (Required)	RASAGILIN	E/CYP1A2 INHIBITORS					
onograph ID	Rasagiline/	CYP1A2 Inhibitors - 2105					
orresponding FDB Interaction ID	2105						
everity Level Code (Required)	3 - Moderat	e Interaction					
equest Assigned To							
inical Effect Code 1 (Required)	Increased e	ffect of the former drug					
linical Effect Code 2							
Di Numper							
Ji i ext							
Facis Number							
r acus Unser							
Facts Decumentation							
Facto Documentation							
icromedex Severity							
cromedex Onset							
icromedex Substantiation							
icromedex Text							
edline Hits							
edline Text							
ackage Insert							
ackage Insert Text							
BM Criteria							
9M Criteria Text							
DS Guidelines							
DS Guidelines Text							
eraction Source							
teraction Type							
ghest Level of Evidence							
roup Discussion							
irrent Action Reason (Required)							
dit							Print Page
	Home	Advanced Query/Customization	Easy Search	Drug Pair Lookup	Reports	Help	

Figure 30: DDI FDB with Custom Records

From here, you can create another custom record if you wish. Checks exist in the system so that the same user cannot make duplicate DDIs *or* another user cannot come in and make the same DDI that another user just made.

Create Multiple DDIs per One FDB Record

- 1. Log on and go to the Advanced Query/Customization tab.
- 2. Choose Drug-Drug Interaction for the Concept.
- 3. Select FDB Records.
- 4. Build the query as follows: Fields=Interaction ID; Filter=Contains; Value= for user guide purposes, let's say 2105.
- 5. Click Query.
- 6. Open Interaction ID 2105 from the list that displays.
- 7. Click Edit.
- 8. Create the custom record by changing something.

9. Your new record is created. The record ID is displayed on the Interaction ID field. If you have any duplicates or other discrepancies, you will see a warning message (such as an identical interaction severity, as shown below):

WITED STATES	ANS AFFAIRS	× ×					
	RMACY ENTI	RPRISE				Welcome, SIX_4	PPROVER Logout
	OMIZATION	SYSTEM					
Home Advanced Query/Custo	nization Eas	y Search Drug Pair Lookup K	ports Help				
Drug-Drug Interaction							Page He
To update this record click on the edi	button below.						
Edit Drug Pairs							Print Page
Warning Messages:							
 A VA Custom interaction already e 	kists for 'RASAGI	INE/CYP1A2 INHIBITORS' with severity	'3'. See below for the o	uplicate VA custom record	details.		
Informational Messages:							
 The associated drug pairs are not 	all reviewed yet.	To submit this interaction as reviewed,	you must review all as	ociated drug pairs. First d	lick on the Dru	g Pairs button then take app	ropriate action.
 Following additional vA custom re 	cord(s) exist for t	he corresponding FDB Drug-Drug inter	action.				
Interaction Type VA Interaction 2020	Interaction ID 334	Interaction Des RASAGILINE/CYP1A2 INHIBITORS	cription	Interaction	Severity	Interaction Ac Approved	tion Status
VA Interaction 2020 EDB Interaction 2105	957	RASAGILINE/CYP1A2 INHIBITORS		9		New	
VA Interaction 2020	360	RASAGILINE/CYP1A2 INHIBITORS		2		Delete Reviewed	
Corresponding FDB Interaction ID	2105						
Interaction Description (Required)	RASAGILINE	CYP1A2 INHIBITORS					
Monograph ID	Rasagiline/0	VP1A2 Inhibitors - 2105					
Action Status	New						
Interaction ID	2020958						
Severity Level Code (Required)	3 - Moderate	Interaction					
Action Date	2012-04-06	D4:26:47					
Action Performed By	SIX_APPRO	/ER					
Request Submitted By	SIX_APPRO	/ER					
Action Effective Date							
Request Assigned To	UNASSIGNE	D					
Clinical Effect Code 1 (Required)	Increased et	fect of the former drug					
Clinical Effect Code 2							
EDI Number							
EDI Text							
DI Facts Number							
DI Facts Onset							
DI Facts Severity							
DI Facts Documentation							
DI Facts Text							
Micromedex Severity							
Micromedex Onset							
Micromedex Substantiation							
Micromedex Text							
Medline Hits							
Medline Text							
Package Insert							
Package Insert Text							
PBM Criteria							
PBM Criteria Text							
AIDS Guidelines							
AIDS Guidelines Text							
Interaction Source							
Interaction Type							
Highest Level of Evidence							
Group Discussion							
Action Reason History	2012/04/06	16:26:47 SIX_APPROVER: Testin	g MMC				
Current Action Reason (Required)							
Edit Drug Pairs							Print Page
	Home	Advanced Query/Customization	Easy Search	Drug Pair Lookup	Reports	Help	

Prevention of Two Users Adding Identical Drug Pairs to the Same DDI

1. After you have created a new DDI or added new drug pairs to an existing DDI, a second user can come in and attempt to add the same drug pairs. If so, they see a message similar to the one circled below:

PECS Home Advanced Que	VETERANS AFFAIRS PHARMACY EN CUSTOMIZATIO ry/Customization	TERPRISE N SYSTEM Isy Search Drug Pair Lookup Reports Help		Welcome, FIVE_APPROVER Logo
rug Pair Customizati	on			Page H
ancel Edit ror Messages:				
Unable to perform the sav	e operation on the cust	umization. (Attempt to create duplicate drug pair: RASAGIL	INE MESYLATE ORAL/MEXILETINE HCL MIS	Interaction Action Status
Interaction	2020958	RASAGILINE/CYP1A2 INHIBITORS	3	New
)B Interaction	2105	RASAGILINE/CYP1A2 INHIBITORS	3	N/A
ner Existing VA Custom Re Interaction Type Interaction Interaction	ecord(s) Interaction ID 2020334 2020957	Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	Interaction Severity 1 9	Interaction Action Status Approved New
Interaction	2020660	RASAGILINE/CYP1A2 INHIBITORS	2	Delete Reviewed
Select Drug Pairs to Drug Pairs	add to the above VA	Custom Interaction		

2. The second user will also receive an error if they attempt to customize drugs that exist for an interaction in reverse order. Note the error messages.

PECS Home Advanced Qu	F VETERANS AFFAIRS PHARMACY ENT CUSTOMIZATION ery/Customization Ease	ERPRISE N SYSTEM sy Search Drug Pair Lookup Repo	orts Help		Welcome, FIVE_APPROVER Logou
Drug Pair Customiza	ition				Page He
Cancel Edit		Attempt to add same drugs in reverse order message		Attempt to create duplica message. Does not sve Customization	te drug pair Drug Pair
rror Messages:					
Another Drug Pair exists	s with the drugs in reverse ave operation on the custo	order. mization (Attempt to create duplicate drug	pair: MEXILETINE HCL MISCEL	LANEOUS/RASAGILINE MESYL	ATE ORAL)
Internetion Trees		Interaction Descr	intion	Interaction Severity	Interaction Action Status
Interaction Lyne	Interaction II)				Interaction Action Status
A Interaction Type	Interaction ID 2020958	RASAGILINE/CYP1A2 INHIBITORS	3		New
A Interaction DB Interaction	2020958 2105	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3		New N/A
A Interaction Type Interaction IDB Interaction ther Existing VA Custom Interaction Type	Record(s)	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri	3 3	Interaction Severity	New N/A Interaction Action Status
(A Interaction Type (A Interaction DB Interaction ther Existing VA Custom Interaction Type (A Interaction	Record(s) 2020334	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS	3 3 iption	Interaction Severity	New N/A Interaction Action Status Approved
Interaction Type A Interaction DB Interaction ther Existing VA Custom Interaction Type A Interaction A Interaction	Interaction ID 2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020957	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 iption 1 9	Interaction Severity	New N/A Interaction Action Status Approved New
Interaction Type A Interaction TDB Interaction Interaction Type A Interaction (A Interaction A Interaction (A Interaction	Interaction ID 2020958 2105 Interaction ID 2020334 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 iption 1 9 2	Interaction Severity	New N/A Approved New Delete Reviewed
Interaction Type A Interaction DB Interaction Interaction Type A Interaction A Interaction A Interaction A Interaction A Interaction A Interaction	Record(s) Interaction ID 202055 2105 Interaction ID 2020334 2020557 2020560	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Custom Interaction	3 3 iption 1 9 2	Interaction Severity	New N/A Approved New Delete Reviewed
Interaction Type A Interaction DB Interaction Interaction Type A Interaction A Interaction A Interaction A Interaction Select Drug Pairs Drug Pairs	Interaction ID 2020958 2105 Record(s) Interaction ID 2020334 2020957 2020660 o add to the above VA	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Custom Interaction	3 3 iption 1 9 2	Interaction Severity	New N/A Interaction Action Status Approved New Delete Reviewed
Interaction Type A Interaction IDB Interaction Interaction Type A Interaction A Interaction A Interaction A Interaction Select Drug Pairs t Drug Pairs	Interaction ID 2020958 2105 Record(s) Interaction ID 2020334 2020937 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Interaction Descri RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS Custom Interaction	3 3 iption 1 9 2	Interaction Severity	New N/A Approved New Delete Reviewed

Drug Pair Detail Page

The Drug Pair detail page allows you to view the details of an FDB Drug Pair or a VA Customized Drug Pair. In either case, this page is read only and the Drug Pair cannot be customized or modified from this page. Customization or modification of Drug Pairs is done through the VA Custom Drug-Drug Interaction detail page. See <u>Drug Pair Customization</u> for information on customizing drug pairs.

If you open an FDB Drug Pair that has been customized once, you will be presented with the customized Drug Pair and a link to the associated VA Drug-Drug Interaction ID.

WITED STATES DEPARTMENT OF VETER	ANS AFFAIR	RS -					
PECS	RMACY E	NTERPRISE ON SYSTEM				Welcome, ONE_APP	ROVER <u>Loqout</u>
Home Advanced Query/Cust	omization	Easy Search Drug Pair Lookup	Reports Help				
Drug Pairs (read-only)							Page Helf
							Print Page
Informational Messages:							
The selected drug pair is associated Further customization or deletion of the	with the VA cu his drug pair ca	stom interaction '2019814 - DOFETILIDE/k an only be done through the VA custom Dr	HYDROCHLOROTHIAZ ug-Drug Interaction deta	IDE' with severity '1'. See bel ail page.	ow for the duplicate	e VA custom record details.	
Action Status	Approved	t					
Interaction ID (Required)	2019814	- DOFETILIDE/HYDROCHLOROTHIAZID	E				
Severity Level Description	Contraine	dicated Drug Combination					
Corresponding FDB Interaction ID	1151						
Request Submitted By	009.18	81					
Request Assigned To	EOS JAR	C1					
Action Effective Date	2010-05-	05 12:54:27					
Action Performed By	69.CB	A EDIADOR					
Action Date	2010-05-	05 12:54:27					
Routed Generic #2 (Required)	HYDRAL	AZINE HCL/RESERPINE/HYDROCHLOR	OTHIAZIDE ORAL				
Routed Generic #1 (Required)	DOFETIL	IDE ORAL					
Reference Text							
Action Reason History							
Current Action Reason (Required)							
							Print Page
	Home	Advanced Query/Customization	Easy Search	Drug Pair Lookup	Reports	<u>Help</u>	
PECS Software Version							

Figure 31: Drug Pair Detail Page (Read Only)

It is possible that an FDB Drug Pair can be customized more than once. For example; a Drug Pair can be customized for a VA Drug-Drug Interaction and then subsequently rejected or deleted from that VA Drug-Drug Interaction and customized a second time for a different VA Drug-Drug Interaction. In this case, when you open the FDB Drug Pair record, you will be presented with the latest customized Drug Pair, a link to the associated VA Drug-Drug Interaction, and an informational messages indicating that the Drug Pair was customized more than once. Two examples follow:

The following example shows what will display if you open an FDB Drug Pair that was customized for VA Drug-Drug interaction 2019814, deleted from VA Drug-Drug interaction 2019814, and then customized a second time for VA Drug-Drug interaction 2021653. Note the informational messages.

WOULD STATES DEPARTMENT OF VETER PECS PHA CUST Home Advanced Query/Custo	ANS AFFAIRS RMACY ENTERPRISE TOMIZATION SYSTEM Welcome, O mization Easy Search Drug Pair Lookup Reports Help	NE_APPROVER <u>Loqout</u>
Drug Pairs (read-only)		<u>Page Help</u>
		Print Page
Informational Messages:		
The selected drug pair is also associa The selected drug pair is associated v Further customization or deletion of th	ted with VA Custom Interaction 2019814 - DOFETILIDE/HYDROCHLOROTHIAZIDE with severity level 1 and in the Deleted action status. with the VA custom interaction '2021653 - DOFETILIDE/HYDROCHLOROTHIAZIDE' with severity '2'. See below for the duplicate VA custom record is drug pair can only be done through the VA custom Drug-Drug Interaction detail page.	d details.
Action Status	New	
Interaction ID (Required)	2021653 - DOFETILIDE/HYDROCHLOROTHIAZIDE	
Severity Level Description	Severe Interaction	
Corresponding FDB Interaction ID	1151	
Request Submitted By	TWO_APPROVER	
Request Assigned To	UNASSIGNED	
Action Effective Date		
Action Performed By	TWO_APPROVER	
Action Date	2013-01-17 14:53:14	
Routed Generic #2 (Required)	CAPTOPRIL/HYDROCHLOROTHIAZIDE ORAL	
Routed Generic #1 (Required)	DOFETILIDE ORAL	
Reference Text		
Action Reason History		
Current Action Reason (Required)		
		Print Page
	Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	

PECS Software Version: 3.0.06.333

Figure 32: Example of FDB Drug Pair Customized for One DDI, Deleted from Another, and Customized for a Third

The following example shows what will display if the user opens an FDB Drug Pair that was customized for VA Drug-Drug Interaction 2019814, rejected from VA Drug-Drug Interaction 2019814, and then customized a second time for VA Drug-Drug Interaction 2021653. Note the informational messages.

WINTED STATES DEPARTMENT OF VETER PECS PHA CUS	ANS AFFAIRS RMACY ENTERPRISE TOMIZATION SYSTEM Provide the service of the serv	PROVER <u>Loqout</u>		
Drug Pairs (read-only)		Page Help		
		Print Page		
Informational Messages:				
The selected drug pair is also associated with VA Custom Interaction 2019814 - DOFETILIDE/HYDROCHLOROTHIAZIDE with severity level 1 and in the Rejected action status. The selected drug pair is associated with the VA custom interaction '2021653 - DOFETILIDE/HYDROCHLOROTHIAZIDE' with severity '2'. See below for the duplicate VA custom record details. Further customization or deletion of this drug pair can only be done through the VA custom Drug-Drug Interaction detail page.				
Action Status	New			
Interaction ID (Required)	2021653 - DOFETILIDE/HYDROCHLOROTHIAZIDE			
Severity Level Description	Severe Interaction			
Corresponding FDB Interaction ID	1151			
Request Submitted By	TWO_APPROVER			
Request Assigned To	UNASSIGNED			
Action Effective Date				
Action Performed By	TWO_APPROVER			
Action Date	2013-01-17 15:13:39			
Routed Generic #2 (Required)	METOPROLOL SUCCINATE/HYDROCHLOROTHIAZIDE ORAL			
Routed Generic #1 (Required)	DOFETILIDE ORAL			
Reference Text				
Action Reason History				
Current Action Reason (Required)				
		Print Page		
-	Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help			

PECS Software Version: 3.0.06.333

Figure 33: Example of Drug Pair Customized for One DDI, Rejected from the Same DDI, and Customized Again for Another DDI.

VA Customized Drug Pair Detail Page

When you opens a VA Customized drug pair, you will be presented with the customized Drug Pair as follows:



PECS Software Version:

Figure 34: VA Customized Drug Pair

Field Descriptions for FDB and VA Custom Drug Pair Detail Page

Action Status	Applicable to VA record only. The point this customization is at, within the VA Approval Workflow.	
Corresponding FDB Interaction ID	The Interaction ID of the FDB record from which the VA Drug interaction customization was created.	
Request Submitted by	Applicable to VA record only. The name of the user that submitted this VA request.	
Action Effective Date	Applicable to VA record only. The date of the last action taken on the record.	
Action Date	Applicable to VA record only. The date of the last action taken on the record.	
Action Performed By	Applicable to VA record only. The name of the user that performed the action.	
Request Assigned To	Applicable to VA record only. A drop down list to select an assigned user.	
---------------------------------	---	
Interaction ID (required)	The VA Custom Interaction ID that the drug pair is associated with.	
Severity Level Descripton	The level of severity for this Drug-Drug Interaction.	
Routed Generic #1 (required)	The first drug in this Drug Pair.	
Routed Generic #2 (required)	The second drug in this Drug Pair.	
Reference Text	Field for the user to enter any reference text needed to support customization of the drug pair.	
Action Reason History	Applicable to VA record only. All historical 'current action reason' comments for this record, in one viewable field.	
Current Action Reason	Applicable to VA record only. Free form text that can be used to specify the reason for taking the specific action of creating new, modifying, assigning, rejecting, reviewing, approving, or deleting the customization.	

Buttons

Print Page	Allows the user to print the page being viewed
------------	--

(This page included for two-sided copying.)

Quick Selection of Drug Pairs from the Selection List

When adding FDB Drug Pairs to an interaction on the Batch Customization page, you may select single drug pairs, groups of consecutive drug pairs, or a combination of both.

To select single drug pairs, simply click on the corresponding checkboxes of the drug pairs you want to select.

•	Select Drug Pairs to add to the above VA	A Custom	Interaction		
Selec	t Drug Pair(s) Source				
Drug	pairs from corresponding FDB Interaction	۲	Existing customized Drug Pairs for this	FDB Drug-Drug Interaction are not displayed.	
Drug	pair from Routed Generic Drug lists	0			
Selec	ct from list of FDB drug pairs - note that at lea	st one dru	g pair must be chosen before clicking th	he Customize button.	
	Routed Generic #1 Description			Routed Generic #2 Description	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BASIC MISCELLANEOUS		LANEOUS	TRANDOLAPRIL/VERAPAMIL HCL ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BASIC MISCELEAREOUS		LANEOUS	ENALAPRIL MALEATE/FELODIPINE ORAL	
-	BISACODYL/SODIUM PHOS,M-BASIC-D-BASIC MISCELLANEOUS BISACODYL/SODIUM PHOS,M-BASIC-D-BASIC MISCELLANEOUS BISACODYL/SODIUM PHOS M-BASIC-D-BASIC MISCEL LANEOUS			PERINDOPRIL ERBUMINE ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE ORAL	
1	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	TELMISARTAN ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	IRBESARTAN/HYDROCHLOROTHIAZIDE ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	QUINAPRIL HCL/HYDROCHLOROTHIAZIDE/MAGNESIUM CARBONATE ORAL	

Figure 35: Select Single Drug Pairs

To select groups of consecutive drug pairs, click on the first checkbox in the group and then shift/click on the last checkbox in the group. All drug pairs between the first and last checkboxes will be selected. If you wish to add another group to your selection, simply click on the first checkbox in the second group and shift/click on the last checkbox in the group. You will now have two groups of drug pairs selected. To add other non-consecutive drug pairs, click on the corresponding checkbox.

Druc	pairs from corresponding FDB Interaction	۲	Existing customized Drug Pairs for	r this FDB Drug-Drug Interaction are not displayed.
Drug	pair from Routed Generic Drug lists	0		
eleo	ct from list of FDB drug pairs - note that at lea	st one dru	g pair must be chosen before clicki	ing the Customize button.
	Routed Generic #1 Description			Routed Generic #2 Description
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	TRANDOLAPRIL/VERAPAMIL HCL ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	ENALAPRIL MALEATE/FELODIPINE ORAL
~	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	PERINDOPRIL ERBUMINE ORAL
/	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	TELMISARTAN ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	IRBESARTAN/HYDROCHLOROTHIAZIDE ORAL
~	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEI	LLANEOUS	QUINAPRIL HCL/HYDROCHLOROTHIAZIDE/MAGNESIUM CARBONATE ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	OLMESARTAN MEDOXOMIL ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	EPROSARTAN MESYLATE/HYDROCHLOROTHIAZIDE ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	AMLODIPINE BESYLATE/VALSARTAN ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	AMLODIPINE BESYLATE/VALSARTAN/HYDROCHLOROTHIAZIDE ORAL
~	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEL	LANEOUS	QUINAPRIL HCL ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	IC MISCEI	LANEOUS	OUINAPRIL HCL/HYDROCHLOROTHIAZIDE ORAL

Figure 36: Range of Drug Pairs Selected with Shift Key

(This page included for two-sided copying.)

Forward and Reverse Professional Monograph

A single VA Custom Drug-Drug Interaction could be associated with a separate custom Professional Monograph for the forward and reverse interactions. An interaction described as Drug A and Drug B would have a different Custom Monograph from an interaction described as Drug B and Drug A. These different monographs may be necessary because there could be a different Clinical Effect Code between forward and reverse interactions (DrugA+DrugB: Clinical Effect Code = Adverse effects of the former drug; DrugB+DrugA: Clinical Effect Code = Adverse effects of the latter drug).

The following VA Custom Professional Monograph pairs will be associated with each other. This means that when a Monograph is assigned to a VA Custom Drug-Drug Interaction, the corresponding Monograph will be automatically assigned to the reverse Drug-Drug Interaction (DDI1 = DrugA + DrugB; DDI2 = DrugB+DrugA).

Monograph ID and Title	Paired Monograph ID and Title
150022 VA Customized: Adverse Effects of Former	150024 VA Customized: Adverse Effects of Latter Drug
Drug (Critical) (ARF1)	(Critical) (ARL1)
150023 VA Customized: Adverse Effects of the Former	150025 VA Customized: Adverse Effects of the Latter
Drug (Significant) (ARF2)	Drug (Significant) (ARL2)
150030 VA Customized: Decreased Effects (Critical)	150032 VA Customized: Decreased Effects (Critical)
(DEF1)	(DEL1)
150031 VA Customized: Decreased Effects (Significant)	150033 VA Customized: Decreased Effects (Significant)
(DEF2)	(DEL2)
150034 VA Customized: Increased Effects (Critical)	150036 VA Customized: Increased Effects (Critical)
(INF1)	(INL1)
150035 VA Customized: Increased Effects (Significant)	150037 VA Customized: Increased Effects (Significant)
(INF2)	(INL2)
150040 VA Customized: Mixed Effects of Former Drug	150103 VA Customized: Mixed Effects of Latter Drug
(Critical) (MXF1)	(Critical) (MXL1)
150041 VA Customized: Mixed Effects of the Former Drug (Significant) (MXF2)	150104 VA Customized: Mixed Effects of the LatterDrug (Significant) (MXL2)

When viewing a Drug-Drug Interaction, the PECS user interface will display only the Professional Monograph associated with the Forward interaction. The associated Reverse Professional Monograph will be visible only in the custom updates file created by the Release Manager.

Forward/Reverse DDI, Same PM
FDBCUSTOMDDIMINTERACTION.TXT - Notepad
File Edit Format View Help
2020183 1 SIMVASTATIN/DILTIAZEM 2 2021 VA ARF MXL 2020183 2 DILTIAZEM/SIMVASTATIN 2 2021 VA ARL MXF
2020182 1 MESTRANOL/TOPIRAMATE 2 150031 VA DEF 2020182 2 TOPIRAMATE/MESTRANOL 2 150033 VA DEL
Forward/Reverse DDI, Different PM

Figure 37: Forward/Reverse DDIs with Professional Monographs, Custom Update File Created by Release Manager

(This page included for two-sided copying.)

Easy Search Query Page

This page allows you to easily query for any Drug-Drug Interactions (and associated Professional Monographs) that may exist within PECS for at least two and up to 10 drugs. This page also allows you to search for Duplicate Therapy information for any drug you select. The example shown is for Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy.

		OF VETERANS AFFAIRS		Welcome, ONE_APPROVER Logout
	Home Advanced G	Query/Customization Easy Search	Drug Pair Lookup Reports Help	
	Easy Search			
	Select Search Type		×	Page Help
Ļ		ug-Drug Interaction with Professional Mo	nograph and/or Duplicate Therapy	

Figure 38: Initial Easy Search Window

To begin an Easy Search:

1. From the "Select Search Type" drop-down list, select Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy.' After you select these values, you see the "Select Information Type", "Search and Select Drugs", "Search Results" and "Drugs to Check" panels:

PECS PHARMACY ENTERPRISE CUSTOMIZATION SYSTEM	Welcome, ONE_APPROVER Logout
ome Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	
asy Search	
ect Search Type Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy 💙	Page Help
elect Information Type	
Drug-Drug Interaction with Professional Monograph	
Duplicate Therapy	
earch and Select Drugs	
g	
Search	

Figure 39: Select Drug-Drug Interaction with Professional Monograph and Duplicate Therapy

- 2. Select either the 'Drug-Drug Interaction with Professional Monograph' checkbox, or the 'Duplicate Therapy' checkbox, or both.
 - If you have selected the 'Drug-Drug Interaction with Professional Monograph' checkbox, you must select one of the options provided, Display Severity Levels 1 (contraindicated) and 2 (severe)' or 'Display All Severity Levels'.



- 3. Enter a partial string or whole drug name into the "Search and Select Drugs" field. Note that you can enter multiple partial strings, and the system returns drugs that match on both strings -- the order of the strings and case are ignored.
- 4. Click the "Search" button. The system returns all drugs that contain the partial string/whole drug name entered.

WITED STATES DEPARTMENT OF VETERANS AFFAIRS PECS PHARMACY ENTERPRISE CUSTOMIZATION SYSTEM Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	Welcome, ONE_APPROVER Logout
Easy Search	
Select Search Type Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy 💌	Page Help
Select Information Type	
✓ Drug-Drug Interaction with Professional Monograph	
Display Severity Levels 1 (contraindicated) and 2 (severe)	
O Display All Severity Levels	
Duplicate Therapy	
Search and Select Drugs	
Drug Metyrapone oral	
Search	
Search Results	have the second se

Figure 40: Severity Levels 1 and 2 Selected, and Drug Name to Search

- 5. Within the Search Results box, you can select up to ten drugs to run the Easy Search query for. You can click one drug at a time to select it for inclusion (highlighted). Alternately, you can click one drug, hold down the 'shift' key, and click as many drugs above or below you want to select, or you can click one drug, hold down the 'Ctrl' key to select additional drugs.
- 6. After you have selected all desired drugs, click the "Add to Drugs to Check" button. The selected drugs are moved down to the "Drugs to Check" panel.

- 7. You may perform additional searches to select more drugs, but only ten drugs can be submitted for a query. If you select more than ten, only the first ten drugs are added to the "Drugs to Check" panel and you receive an error message. Note that you can remove a drug from the "Drugs to Check" listing by highlighting it and clicking the 'Remove from Drugs to Check' button. To remove all drugs at once from the "Drugs to Check" listing, click the 'Remove All Drugs to Check".
- 8. When the drugs in the "Drugs to Check" are finalized, click the "Submit" button to run the query.

Here is a sample return:

DEPARTMENT OF VETERANS AFFAIRS	Walance FIVE ADDROVED
PECS PHARMACT ENTERPRISE CUSTOMIZATION SYSTEM	Welcome, HVE_APPROVER Logout
tome Advanced Query/Customization Easy Search Drug Pair Lookup Reports	
asy Search Results	Return to Search
ugs Checked:	
pirin 300 mg Rectal Suppository (GCN: 4371) Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Antiplatelet Torug-excluding antiplatelet ASA 325 mg & below Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin 500 mg Tab. Delayed Release (GCN: 4383) Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin 500 mg Tab. Delayed Release (GCN: 33787) Therapeutic Class: Low dose Asplini (81 mg or less) profen 200 mg Cap (GCN: 13556) Phorepoutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates profen-oxycodone 400 mg-5 mg Tab (GCN: 58402) Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Narcotic Analgesics - IR (with non-analgesic opiates)	
rug - Drug Interaction	
ug - Drug Interaction - VA pirin 300 mg Rectal Suppository (GCN: 4371) iprofen-oxycodone 400 mg-5 mg Tab (GCN: 58402)	
eraction Description: ASPIRIN/IBUPROFEN werity: 2 - Severe Interaction inical Effects: The antiplatelet and cardioprotective effect of aspirin may be decreased if ibuprofen if administered before aspirin.	
Professional Monograph	





Figure 42: Partial Easy Search Results: Professional Monograph

Professional Monograph initially displays as collapsed; you can expand it by clicking the plus sign. Note that some drugs do NOT have a professional monograph to display (this is rare).

Duplicate Therapy	y Results					
Duplicate Therapy - FD)B					
ibuprofen 200mg Cap (aspirin 300mg Rectal S aspirin 500mg Tab, De ibuprofen-oxycodone 40	(GCN: 13556) Suppository (GCN: 4371) elayed Release (GCN: 4383) 00 mg-5 mg Tab (GCN: 58402)					
Therapeutic Class: Duplicate Allowance: n therapy based on the	Non-Steroidal Anti-Inflammator 0 Use of ibuprofen 200 mg Cap ir association to the therapeutic	y (NSAID) & Salicylates o, aspirin 300 mg Rectal Suppository, as drug class Non-Steroidal Anti-Inflamma	pirin 500 mg Tab, Delay atory (NSAID) & Salicylate	ed Release, and ibuprofen- is.	oxycodone 400 mg-5 mg Tal	o may represent a duplication
Link to record in PECS						
Duplicate Therapy - FD)B					
aspirin 300 mg Rectal S aspirin 500 mg Tab, De	Suppository (GCN: 4371) elayed Release (GCN: 4383)					
Therapeutic Class: Duplicate Allowance: Antiplatelet Drug-exclud	Antiplatelet Drug-excluding anti 0 Use of aspirin 300 mg Recta ding antiplatelet ASA 325 mg & t	platelet ASA 325 mg & below Suppository and aspirin 500 mg Tab, D elow.	elayed Release may rep	resent a duplication in thera	apy based on their associatio	on to the therapeutic drug clas
Link to record in PECS						
Duplicate Therapy - FD	DB					
aspirin 300 mg Rectal S aspirin 500 mg Tab, De	Suppository (GCN: 4371) elayed Release (GCN: 4383)					
Therapeutic Class: Duplicate Allowance: Antiplatelet and Antithro	Antiplatelet and Antithrombotic 0 Use of aspirin 300 mg Rectal ombotic Drugs.	Drugs Suppository and aspirin 500 mg Tab, D	elayed Release may rep	resent a duplication in thera	apy based on their associatio	on to the therapeutic drug clas
Link to record in PECS						N
	Home	Advanced Query/Customization	Easy Search	Drug Pair Lookup	Reports	

Figure 43: Partial Easy Search Results - Duplicate Therapy

9. Duplicate Therapy results only display those results that fall outside the value established by the duplicate allowance indicator. In Figure 27, the duplicate allowance indicator for each therapeutic class is 0, indicating that no duplicate drugs in each therapeutic class are allowed. Note that if the duplicate allowance indicator for a therapeutic class had been set to 1, the Duplicate Therapy results for that therapeutic class would no longer display, since they would be within the acceptable duplicate allowance.

Interactions for a Single Drug

Interactions for a Single Drug allows you to generate a report for all the drug pairs that would be returned in VistA for the selected drug. The report displays FDB and Approved VA custom drug pairs with the specified severity level. FDB drug pairs will display only if there is not an corresponding Approved VA customized drug pair.

To perform a Drug Interactions Report Query:

1. Select "Interactions for a Single Drug " from the Select Search Type drop-down list.

Select Search Type		*
	Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy Interactions for a Single Drug	

2. From the Select Information Type panel, choose the desired Severity Level with the appropriate radio button - Severity Level 1 (contraindicated), Severity Level 2 (severe), or Severity Levels 1 (contraindicated) and 2 (severe).

Select Information Type	
 Severity Level 1 (contraindicated) 	
Severity Level 2 (severe)	

- Severity Level 1 (contraindicated) & 2 (severe)
- 3. Enter a partial string or whole drug name into the Drug field and click Search. Items that match the search string are displayed in the Search Results box. The drug list displays the drug name, dose, route of delivery, and the drug's GCN sequence number. Note that if both a dispensable generic drug and dispensable drug are found that have the same GCN sequence number, only the dispensable drug are displayed on the list. Select an entry from the list.

Search and Select Drugs
Drug rifampin Search
Search Results
RIFAMPIN MISCELLANEOUS POWDER (GCN: 23701) RIFAMPIN INTRAVENOUS VIAL (SDV,MDV OR ADDITIVE) 600 MG (GCN: 13645) RIFAMPIN/ISONIAZID/PYRAZINAMIDE ORAL TABLET 120 MG-50 MG-300 MG (GCN: 48591) RIFAMPIN/ISONIAZID ORAL CAPSULE 300 MG-150 MG (GCN: 9320) RIFAMPIN/ISONIAZID/PYRAZINAMIDE ORAL TABLET (GCN: 16502) RIFAMPIN/ISONIAZID ORAL COMBINATION PACKAGE 300 MG (GCN: 9321) RIFAMPIN ORAL CAPSULE 150 MG (GCN: 9322) RIFAMPIN ORAL CAPSULE 300 MG (GCN: 9323) RIFAMPIN MISCELLANEOUS CRYSTALS (GCN: 14444)

4. Click the Generate Report button. The report generates in Excel. It contains the FDB and VA custom drug pairs whose severity level matches the selected severity level and contain a routed generic drug that corresponds to the selected generic dispensable drug or dispensable drug.

(DRUG_PAIR_IN	ION_REPORT[1].xlsx - Micro	osoft Excel		- = 3
	Home Insert Page	e Layout Formulas Di	ata Review View	Add-Ins Get Started A	crobat		🛞 _ 🖘 🗴
	Calibri - 9	- (A` A`) = = =	- Wrap Text	Custom -		Ξ	27 8
P	aste 🥑 B I U - 🖾 -	· <u>· </u> · <u>·</u> = = =	律律 团 Merge & Center	· S · % · .0 .00	Conditional Format Cell Formatting * as Table * Styles *	Insert Delete Format	Sort & Find & "Filter "Select "
CI	pboard 🖻 🛛 Font	6	Alignment	🗟 Number 🕞	Styles	Cells	Editing
_	A9 🗸 🔿	<i>f</i> ∗ VA					3
	A	В	С	D	E	F	G
9	VA	CYCLOSPORINE ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	CYCLOSPORINE/RIFAMYCINS	2000561	
10	VA C	CYCLOSPORINE, MODIFIED DRAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	CYCLOSPORINE/RIFAMYCINS	2000561	Į.
11	VA D	DABIGATRAN ETEXILATE MESYLATE ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	DABIGATRAN/RIFAMPIN	2020305	
12	FDB C	DARUNAVIR ETHANOLATE DRAL	1-Contraindicated Drug SELECTED 3A4 RIFAMPIN MISCELLANEOUS Combination SUBSTRATES/RIFAMPIN				
13	FDB D	DELAVIRDINE MESYLATE ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	DELAVIRDINE/RIFAMPIN; RIFABUTIN	1038	
14	FDB C	ELVITEGRAVIR/COBICISTAT/E MTRICITABINE/TENOFOVIR DRAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	SELECTED 3A4 SUBSTRATES/RIFAMPIN	434	
15	E FDB F	EMTRICITABINE/RILPIVIRINE HCL/TENOFOVIR DISOPROXIL FUMARATE ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	RILPIVIRINE/CYP 3A4 INDUCERS	2145	
16	VA E	ERLOTINIB HCL ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	SLT ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS/RIFAMYCINS	2020394	
17	FDB E	ETRAVIRINE ORAL	RIFAMPIN MISCELLANEOUS	1-Contraindicated Drug Combination	ETRAVIRINE; NEVIRAPINE/RIFAMPIN; RIFAPENTINE	1428	
	F	FLUCONAZOLE IN DEXTROSE,		1-Contraindicated Drug	AZOLE ANTIFUNGAL		
14	4 P PI DRUE BUTCH			p	al.		> 1

Potential Discrepancy Between Easy Search Results and PECS Records

The custom detail pages in PECS (e.g., <u>Figure 20: Dose Range</u>, <u>Figure 21: Professional Monograph</u>, and <u>Figure 22: Duplicate Therapy</u>) show the custom record as it exists in PECS. These detail pages are accessed through either the Advanced Query/Customization tab, or by clicking the "Link to record in PECS" link found on the Easy Search Results screens.

When you use Easy Search to look up Drug-Drug Interactions or Duplicate Therapy, in the background you are searching a different database table than the one used to store the actual PECS record. The Easy Search results page shows only data from custom records in an Approved state that have been exported in a custom update and processed by an external process named DATUP. If a custom record hasn't gone through these steps, you will see the FDB record and there will be a discrepancy.

Also, if a previously approved/exported custom record is updated, Easy Search will not show the updated data in the results page until the record is approved, exported, and processed by DATUP. Instead, Easy Search will show the custom record results that were last uploaded to DATUP.

Here is an example. Do the following:

- 1. Click the Easy Search tab from the home page.
- 2. Select Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy from the drop-down.
- 3. Select the Drug-Drug Interaction with Professional Monograph check box.
- 4. Select the Display All Severity Levels radio button.
- 5. Enter "fluti" in the search box,
- 6. From the list of drugs, select fluticasone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) to be included in the search.
- 7. Enter "lopinavir" in the search box.
- 8. From the list of drugs, select lopinavir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600) to be included in the search.
- 9. Click Submit.

Here is a sample of the Easy Search screen you see:

me Advanced Query/Customization Face Garch Drug Pair Lookun Reports Help	
	Return to Search
s Checked:	Page Hair
asone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) Therapeutic Class: Nasal Steroids navir-ritonavir 133.3 mg Cap (GCN: 46600) Therapeutic Class: Antiviral-HIV (Antivrat) Protease Inhibitor Therapeutic Class: Selected Antivral-HIV Protease Inhibitors Therapeutic Class: Ritonavir	
ug - Drug Interaction	
g - Drug Interaction - VA	
asone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) navir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600)	
action Description: SELECTED INHALED CORTICOSTEROIDS/PROTEASE INHIBITORS prity: 3 - Moderate Interaction Ical Effects: No Professional Monograph is associated to this Drug-Drug Interaction to record in PECS	
g - Drug Interaction - VA	
casone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) Note Interaction Description Name navir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600)	
action Description FLUTICASONE/RITONAVIR arity: 1 - Contraindicated Drug Combinetion ical Effects: Concurrent use of ritonavir may result in increased systemic exposure to and effects from budesonide, dexamethasone, flu hing's syndrome and adrenal suppression.	dicasone, prednisolone, and triamcinolone, including
to record in PECS	
Professional Monograph	

Figure 44: Easy Search DDI Record

Note the second Interaction Description Name, as is shown above (FLUTICASONE/RITONAVIR) Now, click the "Link to record in PECS" link as is shown above. The next picture displays the name discrepancy.

WITED STATES DEPARTMENT OF VETERAN PECS PHARM CUSTO Home Advanced Query/Customiz	S AFFAIRS MACY ENTERPRISE MIZATION SYSTEM ation Easy Search Drug Pair Lookup Reports Help	Welcome, FIVE_APPROVER Logout
Drug-Drug Interaction		
Drug Pairs	Interaction Description Names are not the	Print Page
Interaction Description (Required)	SELECTED CORTICOSTEROIDS/RITONAVIR	
Monograph ID	Selected Conticosteroids/Ritonavir - 1333	~
Action Status	Approved	
Corresponding FDB Interaction ID	1333	
Interaction ID (Required)	2013331	
Severity Level Code (Required)	1 - Contraindicated Drug Combination	v

Figure 45: Referenced PECS Record with Name Discrepancy

This potential discrepancy applies to Drug-Drug Interaction, Professional Monograph, Duplicate Therapy, and Dose Range concepts.

Easy Search Dose Range

This page allows you to easily query the appropriate dosage information based on the patient and dose particulars entered for a selected drug. The results of this query allows you to ensure the amount being prescribed is an acceptable amount.

To begin a Dose Range Easy Search:

- 1. From the "Select Search Type" drop-down list, select 'Dose Range.'
- 2. Enter a partial string or whole drug name into the "Drug" field. Note that you can enter multiple partial strings, and the system returns drugs that match on both strings -- the order of the strings and case are ignored.
- 3. Click the "Search" button. The system returns all drugs that contain the partial string/whole drug name entered.
- 4. Within the Search Results box, you can select a single drug to run the Easy Search query for by clicking the drug to select it for inclusion (highlighted). Note that if the drug does not have a defined dose route and/or a defined dose unit, the query will not be able to be performed. (Query on aspartame and select aspartame Powder (GCN: 48696) for an example)
- 5. After you have selected the desired drug, the Selected Drug box is populated with drug information for the selected drug and Dose Type and Dose Route drop downs are populated.
- 6. Patient demographic information defaults, and if the Add Default BSA checkbox remains checked, the body surface area value displays. Note that as the fields are updated to match the patient specifics, the body surface area is automatically recalculated.
- 7. The Single Dose and Frequency fields in the Dosing Information default to 1. The Dose Unit dropdown only contains values associated with the selected drug. Note that a blank option exists in the Does Rate Unit dropdown because this field is not required for oral doses.
- 8. When the fields in the Demographic Information and Dosing Information, are finalized, click the "Submit" button to run the query.

(This page included for two-sided copying.)

User Roles

Requestor

The Requestor's role is to create customization requests, modify their own requests, and run, save, and export queries.

Approver

The Approver's role is to create, review, approve, modify, delete or reject customization requests. They also run, save, and export queries, and run reports. An approver can review but cannot approve their own requests.

Release Manager

The Release Manager's role is to handle custom updates. Custom updates can be run at any time, but not more than once per day. The custom update will contain any custom records that have been APPROVED or DELETED since the previous custom update and can be for any of the five main PECS concepts (Dose Range, Drug Pairs, Drug-Drug Interaction, Duplicate Therapy, and Professional Monograph).

Release Managers can search for and view records but they are not allowed to create or approve customizations. They run custom updates at the instruction of the PECS Administrator and/or the National Drug File (NDF) Support Group. They will send an Outlook email to the PECS Administrators after the update has been created.

Here are the steps a Release Manager takes to run a custom update:

- 1. Log in to PECS.
- 2. Click the Custom Update tab:

PECS PHARMACT	Custom Updates	PECS Release Manag page - click Custom U to run update	ger's home pdates tab is		Welcome, THREE_CUSTOM Logout
Icome THREE_CUSTOM					Page Hel
update to First Databank DiF database of	ccurred on: 04-13-2012	version, 3.2			
customization update file creation occurre	ed on: 04-11-2012				
t customization update file creation occurr	ed on: 04-11-2012 <u>Home</u>	Advanced Query/Customization Cus	stom Updates <u>H</u>	lelp	

3. Click Create New Update button:

			Welcome, THREE_CUSTOM Logo
Home Adv	anced Query/Customization	Custom Updates Help	
ustomizatio	n Update Files		Page H
Create New l	Jpdate		
JEICUL	Created Date	Version Comment	
ownload	04-11-2012	Incremental Update File Version: 3.2.710, Created by: THREE_CUSTOM	
ownload	04-11-2012	Full Update File Version: 3.2.711, Created by: THREE_CUSTOM	
ownload	04-04-2012	Full Opdate File Version: 3.2.693, Created by: THREE_COSTOM	
ownload	04-04-2012	Incremental Update File Version: 3.2.692, Created by: THREE_CUSTOM	
ownload	04-03-2012	Incremental Update File Version: 3.2.590, Created by: THREE_COSTOM	
ownload	04-03-2012	Full Update File Version: 3.2.691, Created by: THREE_CUSTOM	
ownload	03-29-2012	Evel Update File Version: 3.2.670, Created by: THREE_CUSTOM	
ownload	03-29-2012	Full Update File Version: 3.2.671, Created by: THREE_COSTOM	
ownload	03-21-2012	Incremental Lindate File Version: 2.2,652, Created by THREE_COSTOM	
ownload	03-21-2012	Incremental Update File Version: 3.2.650, Created by: THREE_COSTOM	
ownload	02-21-2012	Full Lindate File Version: 3.2.651 Created by: THREE_CUSTOM	
ownload	02-16-2012	Full Update File Version: 3.2.631, Created by: THREE_COSTOM	
ownload	03-16-2012	Incremental Lindate File Version: 3.2.630, Created by: THREE_OUSTOM	
lownload	03-13-2012	Full Undate File Version: 3.2.638, Created by: PBMSUPER_USER	
lownload	03-13-2012	Incremental Lindate File Version: 3.2.612. Created by PBMSLIPER LISER	
lownload	03-12-2012	Incremental Undate File Version: 3.2.610, Created by: THREE, CUSTOM	
lownload	03-12-2012	Full Update File Version: 3.2.611, Created by THREE, CUSTOM	
lownload	03-09-2012	Incremental Undate File Version: 3.2.594 Created by THREE_CUSTOM	
ownload	03-09-2012	Full Update File Version: 3.2.595. Created by: THREE_CUSTOM	
ownload	03-08-2012	Full Update File Version: 3.2.593, Created by: THREE_CUSTOM	
ownload	03-08-2012	Incremental Update File Version: 3.2.592, Created by: THREE_CUSTOM	
ownload	03-07-2012	Full Update File Version: 3.2.591, Created by: THREE_CUSTOM	
ownload	03-07-2012	Incremental Update File Version: 3.2.590, Created by: THREE_CUSTOM	
ownload	02-29-2012	Full Update File Version: 3.2.571, Created by: THREE_CUSTOM	
lownload	02-29-2012	Incremental Update File Version: 3.2.570, Created by: THREE_CUSTOM	
ownload	02-22-2012	Full Update File Version: 3.2.554, Created by: THREE_CUSTOM	
ownload	02-22-2012	Incremental Update File Version: 3.2.553, Created by: THREE_CUSTOM	
ownload	02-21-2012	Full Update File Version: 3.2.551, Created by: THREE_CUSTOM	
ownload	02-21-2012	Incremental Update File Version: 3.2.550, Created by: THREE_CUSTOM	
ownload	01-24-2012	Full Update File Version: 3.2.547, Created by: THREE_CUSTOM	
ownload	01-24-2012	Incremental Update File Version: 3.2.548, Created by: THREE_CUSTOM	
lownload	01-24-2012	Incremental Update File Version: 3.2.546, Created by: THREE_CUSTOM	
ownload	01-24-2012	Full Update File Version: 3.2.549, Created by: THREE_CUSTOM	
		In second shall be deter Sile Merchanics & A 500, Annale the TUDEE, AUATOM	

- 4. Verify today's date in Created Date column.
- 5. If an error message is received, report it to PECS Administrator.

Update Files Explained

The custom update files that are run include both a full update and an incremental update. It is rare that a Release Manager will ever have to view these files, but if they do, here is an explanation.

A Custom Update file will always follow the same file naming standard. This standard is:

CstmUpdFile_{FDB Version}.{PECS Generated Version Number}_{Date/Time Stamp}.zip

So a file with the name CstmUpdFile_3.2.751_20120503154622.zip has an FDB Version number of "3.2," a PECS Generated Version Number of "751," and was created on May 3, 2012 at 15:46:22 (military time). The contents of the zip file will determine if this is an Incremental or a Full update.

The custom zip file contains a proddefinition.xml, FDBPRODCONTROL.DAT and several data files that have an extension of UPD. Here is a picture:

Figure 46: Custom Update Zip File

The proddefinition.xml file is a file from FDB that defines the table structures for the FDB tables in an XML format. The FDBUPDCONTROL.DAT file contains control information used by the FDB Data Updater software when determining if this Incremental update should be applied to a database. The UPD files contain data updates for a particular FDB table in the database.

Here is a sample: Note that the "D", "C", and "A" in the left column mean Delete, Change, and Add, respectively.

E[10]1]rtgenid1]2]rtgenid2]3]interactionid[4]segno[5]uicategorv1]6]uicategorv2]7]uicategorv3]8]uicateg
ory4 9 uicategory5 10 uicategory6
P 4 1 2 3 4
D 1052533 1050026 2020134 1
D 1050026 1052533 2020134 2
D 10489717 1050028 2020134 1
D 1050028 10489717 2020134 2
D 1052533 1050027 2020134 1
D 1050027 1052533 2020134 2

Figure 47: Custom Update Text File

The full update contains text files.

Name 🔺	Туре	Packe	Has	Size	R	Date
CTVERSION.TXT	Text Document	1 KB	No	1 KB	0%	5/3/2012 3:46 PM
FDBCUSTOMDDIM.TXT	Text Document	523 KB	No	4,25	88%	5/3/2012 3:46 PM
FDBCUSTOMDDIMINTERACTION.TXT	Text Document	20 KB	No	95 KB	80%	5/3/2012 3:46 PM
FDBCUSTOMDDIMSTRINGS.TXT	Text Document	4 KB	No	18 KB	78%	5/3/2012 3:46 PM
FDBCUSTOMDOSERANGE.TXT	Text Document	2 KB	No	10 KB	85%	5/3/2012 3:46 PM
FDBCUSTOMDUPLICATETHERAPY.TXT	Text Document	1 KB	No	1 KB	42%	5/3/2012 3:46 PM
FDBCUSTOMMONOGRAPH.TXT	Text Document	24 KB	No	115 KB	80%	5/3/2012 3:46 PM
🖬 FILECOUNTS.DAT	DAT File	1 KB	No	1 KB	55%	5/3/2012 3:46 PM
📄 proddefinition.×ml	XML Document	2 KB	No	13 KB	90%	5/3/2012 3:46 PM

Figure 48: Full Update File

Here is a sample of the full update of Drug-Drug Interactions:

	_
1048627 1050000 2004892 1 VA	
1050000 1048627 2004892 2 VA	
1048627 1050001 2004892 1 VA	
1050001 1048627 2004892 2 VA	
1048627 1050014 2004892 1 VA	
1050014 1048627 2004892 2 VA	
1048627 1050015 2004892 1 VA	
1050015 1048627 2004892 2 VA	
1048627 1052651 2004892 1 VA	
1052651 1048627 2004892 2 VA	
1048627 23070090 2004892 1 VA	
23070090 1048627 2004892 2 VA	

Figure 49: Custom Drug-Drug Interaction Full Update File

<

Administrator

A PECS Administrator specific maintenance tasks grouped on the Administration tab that are not available to the other User Roles in the application.

The Administrator can work with:

- Advanced Query/Customization Page
- Customize Settings
- <u>Reports</u>
- Null Drug Pair Removal Process

Customize Settings

Use Customize Setting to change the way data appears in various ways related to a specific concept.

(Customize Settings		
	Drug Pair		
	Drug-Drug Interaction		
	Dose Range		
	Duplicate Therapy		
	Professional Monograph		

Customize Settings allows you to change the label name for the Field (Display Name), whether the field should appear in Queries, Detail Pages, and Reports. It also allows you to change the order the individual fields are displayed on their respective pages.

Warning: Changes made on the Settings page will affect all PECS users. Please proceed cautiously.

Customize Drug Pair Settings					Page H
Name	Display Name	Display In Query	Display In Details	Include In Reports	Display Order
RTGENID1_DESC	Routed Generic #1 Des	True False 🔿	True 🔘 False 🖲	True 🔘 False 🖲	1
RTGENID2_DESC	Routed Generic #2 Des	True False 🔿	True O False O	True 🔘 False 🔍	2
INTERACTIONID_DESC	Interaction Description	True 🔍 False 🔿	True 💿 False 🔿	True 🔘 False 🔍	3
SEVERITYLEVELCODE	Severity Level Code	True	True O False O	True O False O	5
ACTION_STATUS	Action Status	True	True 💿 False 🔿	True 💿 False 🔘	6

Change Field Display Name

To change how the name of a field is displayed on the page, modify the contents of the Display Name field.

- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. Modify the contents of the field in the Display Name column.
- 3. Repeat the process as necessary.

4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

Add/Remove Field from Query Options

To add (or remove) a field from Query options

- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. In the Display in Query column, select True to display the field in Query options, select False to prevent the field from displaying in Query options. NOTE: Display in Query options are not available for all fields; some fields are explicitly required to be displayed in the Query options while others are forbidden from being displayed. In these cases, the required display option (True or False) will be the only options displayed and cannot be changed.



- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

Add/Remove Field from Detail Pages

To add (or remove) a field from Detail pages

1. In the Customize <Concept> List, find the name of the database field you want to change.

2. In the Display in Detail column, select True to display the field on the concept Detail page, select False to prevent the field from displaying on the concept Detail page.

Di	splay In Details
True	۲
False	\odot
True	\odot
False	۲
True	۲
False	\odot

- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

Add/Remove Field from Reports

To add (or remove) a field from Reports

- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. In the Include in Reports column, select True to display the field on concept-related reports, select False to prevent the field from displaying on the concept-related reports.

In	clude In Reports
True	۲
False	\odot
True	0
False	•
True	۲
False	

- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

Change Field Display Order

To change the order that the fields appear in Detail pages and drop-down lists, change the adjacent number in the Display Order field. Note that changing the Display Order is an entirely manual process; each field must be changed individually and the order is not validated in any way. Multiple fields can have the same display order.

When all changes are complete, click Save; click Cancel to abandon the changes and return to the Settings page.

	Display Order	
1		
2		
3		
4		
5		
6		
7		

Approver User Settings

The Approver User Settings allow you to add or delete a user with the Approver role.

Delete an Approver

To Delete an Approver User

1. From the Settings tab, click Update User Settings.

Арр	rover User Se	ettings	
	Update User Se	ettings	

2. Select one or more users from the Approver User Name list.

Home Advanced Query/Customizati	on Admin	istration	Reports
Approver User Settings			
Approver User Name	Delete		
APPROVER_ONE	V		
APPROVER_TWO			
APPROVER_THREE			
*Add an Approver User: Save Cancel			

3. Click Save.

4. Click OK to delete the user(s); click Cancel to abandon the delete user operation and return to the Settings page.



Add an Approver

To add a user with the Approver role

- 1. From the Settings tab, click Update User Settings.
- 2. In the Add an Approver User field, type in the name of the person you want to add.
- 3. The name must be in ALL CAPS and include both the first and last name (in that order) separated by an underscore . Examples: FIRSTNAME_LASTNAME, ERIC_SHINSEKI, JOHN_DOE.
- 4. Click Save.
- 5. Click OK to add the approver user; click Cancel to abandon the add user operation.

Are you sure you want to save User Settings?
OK Cancel

Null Drug Pair Removal Process

The purpose of the Null Drug Pair Removal process is to change the status of any VA Drug Pair that contains a null Routed Generic to "Deleted", and to remove the null drug pairs from their associated VA Drug-Drug Interactions. VA Drug Pairs end up with null Routed Generics because one or both of the Routed Generics that make up the Drug Pair has been deleted by FDB. PECS applies the FDB Routed Generic deletes as part of the weekly FDB MedKnowledge Framework update, so it is recommended that the Null Drug Pair Removal process be run weekly, after the FDB MedKnowledge Framework update completes.

The Administrator may initiate this process at any time by clicking the "Null Drug Pair Removal" button on the following window:

WINTED STATES DEPARTMENT OF VETERANS AFFAIRS PECS PHARMACY ENTERPRISE CUSTOMIZATION SYSTEM			
Home Advanced Query/Customization	Administration	Reports Help	
Administration			
Customize Settings			
Drug Pair Drug-Drug Interaction Dose Range Duplicate Therapy Professional Monograph			
Approver User Settings			
Update User Settings			
Remove Null Drug Pairs			
Click the button below to initiate the Null Drug Pa	ir Removal proces	S.	
Null Drug Pair Removal			

When the process is complete, a message will appear at the top of the page to indicate that the process has completed.

Administration

Informational Messages:

Null Drug Pair Removal processing has completed.

Figure 50: Null Drug Pair Removal Process Complete

Note: The Null Drug Pairs Customization Report can be used to identify *approved* VA Drug-Drug Interactions that contain null Drug Pairs. However, the Null Drug Pair Removal Process removes null drug pairs from *any* VA Drug-Drug Interaction, regardless of status. All VA Custom drug pairs that contain a null routed generic drug are updated as follows: the action status of the drug pair is changed to "Deleted" and the current action reason is "FDB Deleted," with the value of the FDB issue date when the custom drug pair was deleted. The FDB issue date is the date associated with the FDB update file that includes the deletion.

(This page included for two-sided copying.)

Sample Modification Scenarios

The following scenarios are examples of the types of modifications a typical user may perform. It is not a step-by-step guide in instructing users how to perform actual modifications. Sample steps are given, but these could differ based on the customizations being modified.

Duplicate Therapy Modification

Process Steps

Edit duplicate therapy allowance:

- 1. From the Home Page, click the Advanced Query/Customization tab.
- 2. Select "Duplicate Therapy" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the query as follows: Fields=Description; Constraints=contains; Value=Tar.
- 4. Click the Query button.
- 5. Look at the query results at the bottom of the page.
- 6. Click the Open link for the desired class of drug.

7. You see the following:

Home Advanced Query/Custom	ization Easy Search Drug Pair Lookup Reports Help	
Duplicate Therapy		Page H
		Print Page
cid	1026	
istom Dup Allowance <mark>(Required)</mark>	0	~
scription (Required)	Coal Tar Products	
quest Assigned To		×
ference Text		
rrent Action Reason <mark>(Required)</mark>		2
Customize		Print Page

- 8. Click the drop down arrow on Custom Dup Allowance (required).
- 9. Enter a Description (required).
- 10. Enter the Current Action Reason (required).
- 11. Add any reference text you think is needed (optional).
- 12. Click the Customize button.

Duplicate Therapy Approval

Sample Case: After the duplication allowance has been edited for the above situation, you need to submit the request for approval. Assign this request to FOUR_APPROVER.

Process Steps

- 1. From the Home page, look at My Request History.
- 2. Click the link to the NEW Duplicate Therapy requests.
- 3. Look at the query results at the bottom of the page.
- 4. Click the link for the desired class of drug (Topical Pine Tar).
- 5. Review the information.
- 6. Select the next business reviewer's name in Request Assigned To (optional) field.
- 7. Indicate the action reason in Current Action Reason (optional) field.
- 8. Click the Submit As Reviewed button.

Drug Interaction Research

Sample Case: The chief of urology has been told by the Pfizer sales rep that the VA has no drug-drug interaction between sildenafil and tamsulosin. The chief insists that a significant (severity level 2) interaction be added to the system.

Process Steps for Severity Check, Case 1

- 1. Check severity of an existing drug-drug interaction.
- 2. From the Home page, click the Drug Pair Lookup tab.
- 3. Fill in known information (Drug A: Sildenafil; Drug B: Tamsulosin).
- 4. Click the Query button.
- 5. Review the VA custom records and FDB record.
- 6. Note existing VA custom interaction between sildenafil and tamsulosin with severity level 2 and FDB interaction with severity level 3.
- 7. No action needed.

Drug Interaction Severity Change

Sample Case: The FDA recently issued a black box warning stating that cyclosporine and tolterodine should never be used together due to risk of renal toxicity. This interaction is considered severity level 3 (moderate) by First Data Bank. Based on the issuance of this black box warning, the NDF support group is recommending the severity level be changed to 1 (critical). Create custom drug-drug pairs for this new VA custom drug-drug interaction.

Process Steps for Editing Case 1

Edit the severity of an existing FDB drug interaction

- 1. From Home page, choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=cyclosporine.
- 4. Click the And button.
- 5. Build Query: Column=Interaction Description; Constraints=contains; Value=tolterodine.
- 6. Click the And button.
- 7. Click the Query button.
- 8. Look at the query results at the bottom of the page.
- 9. Click the Open link for desired Interaction Description.
- 10. Click the drop down arrow on Severity Level Code (required).
- 11. Select the new desired severity level code (1).
- 12. Indicate the action reason in the free text Current Action Reason (optional) field.
- 13. Click the Customize button.
- 14. Click Drug Pairs button.
- 15. Click plus sign on Select Drug Pairs to add to the above VA Custom interaction bar.
- 16. Click the radio button for "Drug Pairs from Corresponding FDB Interaction."
- 17. Select desired drug pairs to add to the custom interaction
- 18. Indicate the action reason in the free text Current Action Reason (optional) field.
- 19. Click the Customize button.

To Submit as Reviewed:

- 1. From the home page, look at My Assigned Requests for Review.
- 2. Click Drug-Drug Interaction.
- 3. Look at the query results at the bottom of the page.
- 4. Click the link for the desired interaction description (tolterodine/cyclosporine).
- 5. Click the Modify button.
- 6. Review the information.
- 7. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 8. Click the Submit For Review button.
- 9. Choose the Customization tab.
- 10. Click 'VA' under 'Drug-Drug Interaction.'
- 11. Build the Query: Column=Interaction Description; Constraints=contains; Value=tolterodine.

- 12. Click the And button.
- 13. Build the Query: Column=Interaction Description; Constraints=contains; Value=cyclosporine.
- 14. Click the And button.
- 15. Click the Query button.
- 16. Look at the query results at the bottom of the page.
- 17. Select the link for the desired Interaction Description.
- 18. Click the Modify button.
- 19. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 20. Click the Drug Pairs button at the bottom of the page.
- 21. Click the plus sign before 'Select Drug Pairs to add to the above VA Custom Interaction.'
- 22. Click the radio button for 'Select/Deselect all drug pairs from corresponding FDB interaction.'
- 23. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 24. Click the Submit for review button.

(This page included for two-sided copying.)

Drug Interaction Severity Change

Sample Case: Over the past six months, several local VA facilities have reported adverse reactions (ADRs) involving the use of digoxin and metoclopramide resulting in digoxin toxicity requiring hospital admissions for management. This interaction is classified as severity level 3 (moderate) by FDB and therefore does not create an alert in the physician order entry process. The NDF support group has approved the change of the severity level from 3 to 2 (severe) to provide for order alerts and has assigned you to perform this task. Create custom drug-drug pairs for this new VA custom drug-drug interaction. Then submit the new interaction and drug pairs as reviewed.

Process Steps for Editing Case 2

Edit the severity of an existing FDB drug interaction

- 1. From the Home page, choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=digoxin.
- 4. Click the And button.
- 5. Build the Query: Column=Interaction Description; Constraints=contains; Value=metoclopramide.
- 6. Click the And button.
- 7. Click the Query button.
- 8. Look at the query results at the bottom of the page.
- 9. Click the Active link for the desired Interaction Description.
- 10. Click the drop down arrow on Severity Level Code (required).
- 11. Select the desired new severity level code (2).
- 12. Indicate the action reason in the free text Current Action Reason (optional) field.
- 13. Click the Customize button.
- 14. Click Drug Pairs button.
- 15. Click the plus sign on Select Drug Pairs to add to the above VA Custom interaction bar.
- 16. Click the radio button for 'drug pairs from corresponding FDB interaction.'
- 17. Click the checkbox for 'Select/Deselect all drug Pairs from corresponding FDB interaction.'
- 18. Indicate the action reason in the free text Current Action Reason (optional) box
- 19. Click the Customize button.
- 20. From the Home page, look at My Request History.
- 21. Click the NEW Drug-Drug Interactions link.
- 22. Look at the query results at the bottom of the page.
- 23. Click on the Active link for the desired interaction description (digoxin/metoclopramide).
- 24. Click Drug Pairs button (Drug pairs should be submitted as reviewed prior to submitting the interaction for review)

- 25. Click the plus sign on Drug Pairs Bar
- 26. Click the checkbox for 'Select/Deselect All Drug Pairs Displayed from VA Custom Interaction'
- 27. Click the Submit as Reviewed button.
- 28. Click on the VA Interaction ID at top of page to navigate to Drug Interaction Detail page
- 29. Click the Submit as Reviewed button.
Remove Drug Pair from Interaction

Sample Case: You have been asked to remove the drug pair SUMATRIPTAN NASAL/TRANYLCYPROMINE SULFATE ORAL from the existing VA custom drug-drug interaction SELECTED 5HT-1D AGONISTS/MAO INHIBITORS.

Process Steps

Remove or add a drug pair from an existing VA custom drug-drug interaction.

- 1. Choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'VA' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=SELECTED 5HT.
- 4. Click the And button.
- 5. Click the Query button.
- 6. Look at the query results at the bottom of the page.
- 7. Select the Active link for the desired Interaction Description.
- 8. Click the Drug Pairs button at the bottom of page.
- 9. Click the plus sign on 'Drug Pairs' bar.
- 10. Click on the checkbox associated with Sumatriptan Nasal and Tranylcypromine Sulfate Oral.
- 11. Click the Submit for Delete button.
- 12. Alert another Approver that the drug pair needs to be deleted.

Create Professional Monograph

Sample Case: Create a new VA custom monograph using the current FDB interaction monograph created for cyclosporine and tolterodine as the guide. Modify the FDB monograph severity level from level 3 to level 1 – contraindication.

Process Steps

- 1. Choose the Advanced Query/Customization tab.
- 2. Select "Professional Monograph" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA*, *FDB*, *or Both* drop-down.
- 3. Build the Query: Column=Monograph Title; Constraints=contains; Value=cyclosporine.
- 4. Select "And" from the drop-down.
- 5. Build the Query: Column=Monograph Title; Constraints=contains; Value=tolterodine.
- 6. Click the Query button.
- 7. Look at the results at the bottom of the page.

8. Click the link for the desired monograph title in the FDB table results. The Monograph is displayed, as shown.

Iome Advanced Query/Cust	omization Easy Search Drug Pair Lookup Reports Help	
rofessional Monograph		
	Print Page	i <u>qe Hel</u>
nograph Title <mark>(Required)</mark>	Tolterodine/Cyclosporine	< >
quest Assigned To		*
verity Level <mark>(Required)</mark>	3-Moderate Interaction: Assess the risk to the patient and take action as needed.	~
chanism Of Action		~
chanishi or Action	Cyclosporine may inhibit the metabolism of tolterodine by CFP P-450-384.(1,2)	
nical Effects (Required)	The concurrent administration of tolterodine with cyclosporine may result in elevated levels of tolterodine and signs of toxicity.(1,2)	~
disposing Factors	None determined.	>
		>
ient Management	The manufacturer of tolterodine recommends that a maximum tolterodine dosage of 1 mg twice daily of the non extended release dosage form(1) or 2 mg once daily of the extended release dosage form(2) be used in patient receiving concurrent therapy with cyclosporine.	3
cussion	In a study in eight subjects who were deficient in CYP P-450-2D6, the concurrent administration of tolterodine (2 mg) with ketoconazole (200 mg once daily for four days), another inhibitor of CYP P-450-3A4, resulted in a 60% decrease in tolterodine clearance.(3) Tolterodine AUC and Cmax increased 2.5-fold and 2- fold, respectively.(2)	
ference	 Detrol (tolterodine tartrate) US prescribing information. Pharmacia & Upjohn Company April, 2009. Detrol LA (tolterodine tartrate) US prescribing information. Pharmacia & Upjohn Company September, 2008. Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999 Oct:48(4):564-72. 	
forence Text		~
		~
rrent Action Reason <mark>(Require</mark> d	0	×
		*
Customize	Print Page	

- 9. Change the Severity level to 1 Critical.
- 10. Indicate the action reason in the free text Current Action Reason (optional) field.
- 11. Click the Customize button.

(This page included for two-sided copying.)

Reports

The Reports page displays a list of available reports in PECS. PECS Reports are essentially exported Excel spreadsheets that can be manipulated and formatted as the user sees fit.

Note, the Reports page is not visible to Requestor role users.

To run a report, click the link associated with it. You will be provided the option of opening the file directly or saving it to copy of the file to a location on your workstation (or accessible network location).

Customization Reports

The following sections describe the customization reports.

FDB Custom Dose Range Report

The FDB Custom Dose Range Report contains active VA custom Dose Range records in an Approved status along with their corresponding FDB record data. The default file name is Dosing_Total_Customization_Report.xlsx.

FDB Custom Drug-Drug Interaction Report

The FDB Custom Drug-Drug Interaction Report contains active VA custom Drug-Drug interaction records in an Approved status along with their corresponding FDB record data.

To Run the FDB Custom Drug-Drug Interaction Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Select the FDB Custom Drug-Drug Interaction Report radio button and click the Export button.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). The file name is Ddiminteraction_Total_Customization_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

FDB Custom Duplicate Therapy Report

The FDB Custom Duplicate Therapy Report contains active VA custom Duplicate Therapy records in an Approved status along with their corresponding FDB record data.

To Run the FDB Custom Duplicate Therapy Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Select the FDB Custom Duplicate Therapy Report radio button and click the Export button.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Dtcat_Total_Customization_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

FDB Custom Professional Monograph Report

The FDB Custom Professional Monograph Report contains active VA custom Professional Monograph records in an Approved status along with their corresponding FDB record data.

To run the FDB Custom Professional Monograph Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Select the FDB Custom Professional Monograph Report radio button and click the Export button.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Monograph_Total_Customization_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

Deleted Monograph Customization Report

The Deleted Monograph Customization Report contains active VA custom Drug-Drug interaction records in an Approved status that are associated with a deleted FDB Professional Monograph.

To Run the Deleted Monograph Customization Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Click the Deleted Monograph Customization Report link.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Deleted_Monograph_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

Null Drug Pairs Customization Report

The Null Drug Pairs Customization Report contains approved VA custom Drug-Drug Interactions that contain Drug Pairs with null Routed Generic #1 or Routed Generic #2 fields. If this report contains any entries, it is recommended that a user in the Administrator role initiate the Null Drug pair Removal Process.

To Run the Null Drug Pairs Customization Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Click the Null Drug Pairs Customization Report link.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Deleted_Monograph_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

FDB Comparison Reports

The FDB Comparison Reports display the changes to existing data included in the Incremental FDB updates. They inform an approver or administrator of the latest FDB changes for the Duplicate Therapy, Drug-Drug Interaction, and Drug Pair concepts and provide data that helps them decide whether to change a custom record. The FDB Comparison Reports help an approver or administrator keep PECS customizations in sync with FDB changes.

FDB Comparison Reports display:

- Customized records in all action statuses that have differences between the PECS FDB data and the data in the Incremental FDB Update file.
- Un-customized records that have differences between the PECS FDB data and the data in the Incremental FDB Update file.
- Indications that an FDB record is scheduled to be deleted by DATUP.
- Lists of the drug pairs that will be added or deleted by DATUP.
- A "no data found" message if the Incremental FDB Update file has no changes to the FDB data.

Structure of the FDB Comparison Report

-	DTReport.xlsx							_	-		23
	А	В	С	D	E	F	G	1	н		1
1	FDB Update Received:	20111202					Note: * indicates changed FDB data				
2		Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description				
23	VA Custom	Reviewed	2012-02-17		1210	0	Fat Absorption Decreasing Agents				
24	FDB After Update				1210	2*	Fat Absorption Decreasing Agents				
25	FDB Before Update				1210	0*	Fat Absorption Decreasing Agents				
20	VA Custom	Modified	2012-02-17		1211	1	Procarbazine				
28	EDB After Undate	mounicu	2012 02 17		1211		Procarbazine test *				_
29	FDB Before Update				1211	0	Procarbazine *				
50	roo berore opuate					, in the second s					=
31	VA Custom	New	2012-02-17		1206	0	Manganese				
32	FDB After Update				1206	2*	Manganesee *				_
33	FDB Before Update				1206	0*	Manganese *				_
		Delete									
35	VA Custom	Reviewed	2012-02-17		1204	0	Agents to Treat Resistant Gram Positive Organisms				
36	FDB After Update				1204	1*	Agents to Treat Resistant Gram Positive Organisms				_
37	FDB Before Update				1204	0 *	Agents to Treat Resistant Gram Positive Organisms				
20	VA Custom	Deleted	2012 02 17		1202	0	Antiparkinson h Ropinirala Formulations				
39	EDB After Lindate	Deleted	2012-02-17		1202	0	Antiparkinsonian Ropini ole Formulations				
40	EDB Refere Lindate				1202	0	Antiparkinsonian Ropinirole Formulations test22				
41	i bo berore opuate				1202	U	Antiparkinsonian Ropinitole Formulations				
43											-
H ·	DT FDB Comparis	son Report 🧷	7							<u> </u>	▶:

Figure 51: Sample FDB Comparison Report - Duplicate Therapy

Each FDB Comparison Report lists the "FDB Update Received" date, which is the date listed in the Incremental FDB Update file.

Each report lists comparison sets of VA and FDB data. Each comparison set consists of at least three rows separated by a blue line. The three rows are:

VA Custom	Data in the Custom VA record. If the corresponding FDB record has not been customized a "Not customized" message will be in the Action
	Status column and the rest of the row will be blank.
FDB After Update	Data in the Incremental FDB Update File. This data will be in the PECS
	database shortly after the incremental FDB update is done via DATUP.
FDB Before	Data in the PECS FDB record. This data will be replaced by the 'FDB
Update	After Update' data. If the FDB After Update and FDB Before Update
	data of the same type are different, they are marked with an asterisk (*)
	and colored red. Records that do not have any differences between the
	FDB Before Update and FDB After Update data of the same type are
	not listed in the report.

Each FDB Comparison Report has the following columns:

Action Status	The state of the associated VA record based on the most recent action performed. PECS compares FDB data with VA customizations in any Action Status, including Rejected or Deleted
	Action Status, including Rejected of Deleted.
Action Date	The date the current action (Action Status) was taken.
DATUP will delete	YES in this column Indicates the associated FDB record will be deleted by DATUP. If the column is blank, the associated FDB record will not be deleted by DATUP.
	If the FDB record will be deleted by DATUP, only the FDB Interaction ID and DATUP will delete columns will be filled out in the FDB After

Update row. All the other columns will be blank.

The reports are organized by type and the date of the FDB Incremental Update. Links to the reports are kept for eight weeks on the Reports page.

To run an FDB Comparison report, click the appropriate FDB Incremental Update date under the appropriate Report Heading.

Drug-Drug I	nteraction/	Drug Pairs	k
<u>2012-05-31</u>	<u>2012-05-16</u>	<u>2012-05-09</u>	<u>2012-05-08</u>
2012-05-07	2012-05-04	<u>2012-04-27</u>	
Duplicate TI	herapy		
2012-05-31	2012-05-16	2012-05-09	2012-05-08
2012-05-07	2012-05-04	2012-04-27	

Figure 52: FDB Incremental Update Section Items

If there are no differences between the FDB After Update and FDB Before Update data of the same type in any of the records, a "No Data Found" message is printed on the FDB Comparison Report.

	DTReport.xlsx									-	• 7	23
	А	В	С	D	E	F	G	н	1	J	K	
1	Latest FDB Update:	20111202					Note: * indicates updated information					
2		Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description					
3	NO DATA FOUND											
4												
5												
6												
7												
8												
9												
10												
11												
12												
13												
14												
15												
16												
17												
18												
19												
20												_
11	DT FDB Comp	arison Report 2	* *			1					•	:
	or rob comp										-	

Figure 53: Example of a "No Data Found" Message in an FDB Comparison Report

Drug-Drug Interaction/Drug Pair Report

	DDIReport.xlsx							- 0	23
	А	В	С	D	E	F	G		-
1	FDB Update Received:	20111202					Note: * indicates changed FDB data		
2		Action Status	Action Date	DATUP will delete	VA Interaction ID	FDB Interaction ID	Interaction Description		
28	VA Custom	Rejected	2010-05-11		2002371	237	ERGOT ALKALOIDS/NITRATES		
29	FDB After Update			Yes		237			
30	FDB Before Update					237	ERGOT ALKALOIDS/NITRATES		
22	VA Custom	Deleted	2010 05 05		2012742	1074	STEROIDAL CONTRACEDTIVES A DREDITANT		
32	FDR After Undate	Deleted	2010-03-03	Voc	2012/42	12/4	STEROIDAL CONTRACEPTIVES/APREPITANT		
24	FDB Arter Opuale			Tes		12/4			
34	FDB Before Opdate					12/4	STEROIDAL CONTRACEPTIVES/APREPITANT		
36	VA Custom	Not customized							
37	FDB After Update			Yes		451			
38	FDB Before Update					451	THEOPHYLLINES/TACRINE		
40	VA Custom	Not customized							
41	FDB After Update	noreasternized		Yes		452			
42	FDB Before Update					452	CYCLOSPORINE/BARBITURATES		
45	i be beiere opnote								
44	VA Custom	Not customized							
45	FDB After Update					1623	POSACONAZOLE/CIMETIDINE-HI*		
46	FDB Before Update					1623	POSACONAZOLE/CIMETIDINE *		_
48	VA Custom	Rejected	2010-05-17		2015651	1565	RANOLAZINE/QT PROLONGING AGENTS		
49	VA Custom	Rejected	2010-05-17		2015652	1565	RANOLAZINE/QT PROLONGING AGENTS		-
H -	DDI-DP FDB Com	parison Report /	FDB Interacti	on ID 16-DP / FDB I	Interaction ID 81-DP	FDB 4	-		► 18

Figure 54: DDI-DP Report

The FDB Comparison Drug-Drug Interaction/Drug Pairs Report displays the changes to existing Drug-Drug Interactions included in the Incremental FDB updates. All Action Statuses are compared and are included in the report. The following data points are compared between the FDB update and the VA Drug-Drug Interaction records:

- Corresponding FDB Interaction ID
- Interaction Description
- Monograph ID

- Severity Level Code
- Clinical Effect 1
- Clinical Effect 2
- Deleted Drug Pairs
- Added Drug Pairs

The DDI-DP FDB Comparison Report contains two types of spreadsheets:

- The DDI-DP FDB Comparison Report gives information about the FDB comparisons and the associated VA custom records.
- FDB Interaction ID-DP gives information about the added or deleted drug pairs for a specific FDB record. Each FDB update record that has added or deleted drug pairs has its own FDB Interaction ID-DP spreadsheet.

The following DDI-specific fields are included in the DDI-FDB Comparison Report spreadsheet:

A VA-assigned numerical identifier for the interaction.
An FDB-assigned numerical identifier for the interaction.
A text description of the interaction.
A numerical identifier for the Professional Monograph associated with the interaction.
A coded severity indicator. See Severity Level Codes for additional information.
A three letter code describing the clinical effect. See Clinical Effect Codes for additional information.
A three letter code describing the clinical effect. See Clinical Effect Codes.
If a DDI has drug pairs scheduled to be added or deleted by
DATUP, there will be a message, "See FDB Interaction ID <fdb< td=""></fdb<>
Interaction ID number>-DP."
If a DDI record in the incremental FDB update file does not have added or drug pairs, this column will remain blank.

Here are screen shots of a DDI Comparison Report with the "See FDB Interaction ID <> DP" message and the tab that relates to it. Notice the highlighted row:

А	В	С	D	E	F	G
FDB Update Received:	20111202					Note: * indicates changed FDB data
	Action Status	Action Date	DATUP will delete	VA Interaction ID	FDB Interaction ID	Interaction Description
VA Custom	Modified	2012-03-09		2020866	1581	DROSPIRENONE/ACE INHIBITORS; ARBS
FDB After Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS
FDB Before Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS
VA Custom	New	2012-03-09		2020864	30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
VA Custom	New	2012-03-09		2020865	30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
FDB After Update					30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
FDB Before Update					30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
VA Custom	New	2012-03-14		2020881	112	ANTIDIABETICS, ORAL/SALICYLATES
VA Custom	Modified	2012-03-15		2020882	112	ANTIDIABETICS, ORAL/SALICYLATES
FDB After Update					112	ANTIDIABETICS, ORAL/SALICYLATES-Test *
FDB Before Update					112	ANTIDIABETICS, ORAL/SALICYLATES *
VA Custom	Reviewed	2012-03-01		2020857	31809	QUINOLONES/THEOPHYLLINES
FDB After Update					31809	QUINOLONES/THEOPHYLLINES
FDB Before Update					31809	QUINOLONES/THEOPHYLLINES
VA Custom	Deleted	2012-01-23		2020502	258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
VA Custom	Rejected	2010-05-06		2002582	258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
VA Custom	Approved	2010-05-06		2002581	258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
FDB After Update					258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
FDB Before Update					258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
	Delete					
VA Custom	Reviewed	2012-02-24		2020828	30120	CIPROFLOXACIN/AGOMELATINE
FDB After Update					30120	CIPROFLOXACIN/AGOMELATINE-FUN *
FDB Before Update					30120	CIPROFLOXACIN/AGOMELATINE *
						1
DDI-DP FDB Con	nparison Report	FDB Interacti	on ID 81-DP / FDB	Interaction ID 112-DP	FDB Interaction I	D 1565-DP 2
						The server of the difference of the server o

Figure 55: First Half of FDB Comparison Report for DDI

1 2 Monograph ID	Severity Level	Clinical Effect 1	Clinical Effect 2	Drug Pairs
8 Drospirenone/Ace Inhibitors; ARBs - 1581		Decreased effect of the former drug		
9 Cyclosporine/Calcium Channel Blockers - 258 *		Additive side effects from both drugs		
0 Drospirenone/Ace Inhibitors; ARBs - 1581 *		Additive side effects from both drugs		
2 Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		Increased effect of the latter drug		
3 Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		Increased effect of the latter drug		
4 Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		Adverse reaction of the former drug *		
5 Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		Increased effect of the latter drug *		
7 Antidiabetics, Oral/Salicylates - 112		Increased effect of the former drug		
8 Antidiabetics, Oral/Salicylates - 112		Increased effect of the former drug		
Antidiabetics, Oral/Salicylates - 112	1*	Increased effect of the former drug		See FDB Interaction ID 112-DP
0 Antidiabetics, Oral/Salicylates - 112	3.	Increased effect of the former drug		
2 Theophyllines/Quinolones - 191		Increased effect of the latter drug	Adverse reaction of the former drug	1
3 Theophyllines/Quinolones - 191		Increased effect of the latter drug	Adverse reaction of the former drug *	
4 Theophyllines/Quinolones - 191		2 Increased effect of the latter drug	. /	
Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258		3 Labeling conflicts between countries or products 2 increased effect of the former drug 1 increased effect of the former drug		
9 Cyclosporine/Calcium Channel Blockers - 258	1*	Adverse reaction of the former drug *	Additive side effects from both drugs *	
0 Cyclosporine/Calcium Channel Blockers - 258	3*	Increased effect of the former drug *		
VA Customized: Decreased Effects (Significant) (DE(2) - 150033 (custom) Ranolazine/QT Prolonging Agents - 1565 * Agomelatine/Ciprofloxacin - 1880 *	2* 1*	Increased effect of the latter drug Increased effect of the latter drug Increased effect of the latter drug	Additive side effects from both drugs *	
6 7				
9				
0				
1				
2				
3	/			
4				
5	-			
+ + DDI-DP FDB Comparison Report FDB Interaction ID 81-DP FDB Interact	tion ID 112-DP	DB Interaction ID 1565-DP		

Figure 56: Second Half of FDB Comparison Report for DDI

If the latest FDB update contains added or deleted drug pairs, these will be displayed on separate tabs titled "FDB Interaction ID <FDB Interaction ID number>-DP". Here are the contents of the FDB Interaction ID tab, i.e., the drug pairs that have been updated by FDB:



Figure 57: Contents of the FDB Interaction ID tab, i.e., Drug Pairs Updated by FDB:

If an FDB record has been customized multiple times, all of the customizations will be listed in the report, as shown below:

A	8	C	U	3		U	н
1 FDB Update Received:	20111202					Note: * indicates changed FDB data	
2	Action Status	Action Date		A Interaction ID	FDB Interaction ID	Interaction Description	Monograph ID
54 VA Custom 55 FDB After Update	Approved	2010-05-04	Multiple VA custom updates and their various action statuses	2011561	1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhibitors - 1156
55 FDB Before Update					1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhibitors - 1156
58 VA Custom 59 FDB After Update 60 FDB Before Update	Modified	2012-03-95	\square	2020866	1581 1581 1581	DROSPIRENONE/ACE INHIBITORS; ARBS DROSPIRENONE/ACE INHIBITORS; ARBS DROSPIRENONE/ACE INHIBITORS; ARBS	Drospirenone/Ace Inhibitors; ARBs - 1581 Cyclosporine/Calcium Channel Blockers - 258 * Drospirenone/Ace Inhibitors; ARBs - 1581 *
62 VA Custom 63 VA Custom 64 FDB After Update 65 FDB Ratore Update	New	012-03-09 2012-03-09		2020864 2020865	30786 30786 30786 30786	SELECTED MAGROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE(MACNO DELETED)	Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) -
67 VA Custom 68 VA Custom 69 FDB After Update 70 FDB Before Update	New Modified	2012-05-14 2012/03-15		2020881 2020882	112 112 112 112	ANTIDIABETICS, ORAL/SALICYLATES ANTIDIABETICS, ORAL/SALICYLATES ANTIDIABETICS, ORAL/SALICYLATES-Test * ANTIDIABETICS, ORAL/SALICYLATES *	Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112
72 VA Custom 73 FDB After Update 74 FDB Before Update	Reviewed	2012-03-01		2020857	31809 31809 31809	QUINOLONES/THEOPHYLLINES QUINOLONES/THEOPHYLLINES QUINOLONES/THEOPHYLLINES	Theophyllines/Quinolones - 191 Theophyllines/Quinolones - 191 Theophyllines/Quinolones - 191
76 VA Custom 77 VA Custom 78 VA Custom 79 FDB After Update	Deleted Rejected Approved	2012-01-23 2010-05-06 2010-05-06		2020502 2002582 2002581	258 258 258 258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS CYCLOSPORINE/CALCIUM CHANTEE BLOCKERS CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS	Cyclosporine/Calcium Channel Blockers - 256 Cyclosporine/Calcium Channel Blockers - 256 Cyclosporine/Calcium Channel Blockers - 255 Cyclosporine/Calcium Channel Blockers - 256
80 FDB Before Update					258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS	Cyclosporine/Calcium Channel Blockers - 258

Figure 58: Display of All Customizations Done for an FDB Record

The following fields are included in the FDB Interaction ID-DP spreadsheet:

Routed Generic 1 Description	The Routed Generic Description of Drug 1 in the Drug Pair
Routed Generic 2 Description	The Routed Generic Description of Drug 2 in the Drug Pair
DATUP action	The action that DATUP will perform. DATUP will either add the drug pair to the PECS database or delete it from PECS.

Note: A DDI record that is not listed on the DDI-DT FDB Comparison Report spreadsheet can still have added or deleted drug pairs listed in the latest incremental FDB update file. In that case, the drug pair information is just listed on an FDB Interaction ID-DP spreadsheet.

Duplicate Therapy Report

	А	В	С	D	E	F	G		
1	FDB Update Received:	20120525					Note: * indicates changed FDB data		
2	1	Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description		
3	VA Custom	Approved	2012-05-07		1338	1	Antidiarrheal Formulations with Gut Flora Microorganisms		
4	FDB After Update			Yes	1338				
5	FDB Before Update				1338	0	Antidiarrheal Formulations with Gut Flora Microorganisms		
7	VA Custom	Approved	2012-04-16		376	1	Stimulant Laxatives		
8	FDB After Update			Yes	376				
9	FDB Before Update				376	0	Stimulant Laxatives		
11	VA Custom F	Reviewed	2012-02-23		375	0	Steroids - Mouth		
12	FDB After Update			Yes	375				
13	FDB Before Update				375	0	Steroids - Mouth		
15	VA Custom	Modified	2012 02 22		270	4	Culfanamidas		
15	FDR After Undate	vioaniea	2012-02-23	Voc	378	1	suronamides		
17	FDB Arter Opuale			res	270	0	Sulfonamidos		
10	rob before opdate				578	0	Suronamides		
19	VA Custom F	Reviewed	2012-04-13		1132	0	Thrombin Inhibitors (Non-Heparinoid)		
20	FDB After Update			Yes	1132				
21	FDB Before Update				1132	0	Thrombin Inhibitors (Non-Heparinoid)		
23	VA Custom	Modified	2012-02-23		1213	1	Dantrolene		
24	FDB After Update			Yes	1213				
25	FDB Before Update				1213	0	Dantrolene		
27	VA Custom	Modified	2012-04-09		1456	1	Orotic Acid		
28	FDB After Update			Yes	1456				
29	FDB Before Update				1456	0	Orotic Acid		
31	VA Custom F	Reviewed	2012-02-23		1310	1	Lymphocyte Immune Globulin		
32	FDB After Update			Yes	1310				
33	FDB Before Update				1310	0	Lymphocyte Immune Globulin		
35	VA Custom	Modified	2012-02-23		1319	2	Typhoid Vaccine		
36	FDB After Update			Yes	1319				
37	FDB Before Update				1319	0	Typhoid Vaccine		
20	VA Custom	Not customized							
40	FDB After Undate	tot customizeu		Yes	1564				
41	FDB Before Update				1564	0	Malic Acid		
42	1/4 Currtering	N	2012 02 01		44.54	-			
43	VA Custom	New	2012-02-21	N	1131	0	Nasai Antinistaminės		
44	FUB After Update			res	1131				
45	TUB BETORE Update	n Report	/		1131	0	Nasai Anunistamines		
Rea									

Figure 59: FDB Comparison Report - Duplicate Therapy

The Duplicate Therapy FDB Comparison Report displays the differences between the PECS FDB data and the data in the Incremental FDB Update file for the Duplicate Therapy (DT) concept. This report displays the following DT-specific data:

DTCID	Duplicate Therapy Control ID. A numerical identifier for the DT FDB and VA records.
Dup Allowance	Duplicate Allowance. The number of drugs performing the same function before a warning is issued.
Description	A description (name) of the drug that is the basis of the DT record.

Dose Range Report

Not implemented in this release.